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Abstract
Stem cell transplants (SCTs) are complicated treatments utilized to treat hematologic
malignancies and other disorders, such as multiple myeloma, non-Hodgkin’s lymphoma,
Hodgkin’s lymphoma, acute myeloid leukemia, neuroblastomas, germ cell tumors, amyloidosis,
and autoimmune disorders such as systemic lupus erythematosus and systemic sclerosis. The
complex care of patients undergoing SCTs place them at high risk for adverse outcomes,
including infection, cytomegalovirus, graft vs host disease, secondary new cancers, infertility,
and sexual dysfunction (American Cancer Society, 2020). Survivorship care plans (SCPs) are a
vital part of the discharge process to educate allogenic SCT patients about post-transplantation
care. SCPs are implemented to reduce the risk of common complications and hospital readmissions in post-SCT patients. The purpose of this project is to use SCPs to reduce 30-day readmission rates of allogenic SCT patients. A review of literature was conducted to analyze the
impact of SCPs on post-transplantation knowledge of preventative measures and common
complications. The SCP Questionnaire was created to measure knowledge received from the
SCP to highlight the effectiveness of preventative measures and common complications posttransplantation. Kurt Lewin’s Change Theory provided the underlying theoretical framework for
this project’s implementation process. The methodology used was a non-randomized quasiexperiment with purposive sampling of allogenic patients that included a retrospective chart
review measuring 30-day readmissions, demographics, and the number of patients discharged
post-transplant. The Wilcoxon Signed Ranked Test was utilized to demonstrate statistical
significance in 30-day readmission rates through post-transplant knowledge and managed care.
Keywords: allogenic, stem cell transplants, survivorship care plans, common
complications
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The Effects of a Survivorship Care Plan on Hospital Readmission Rates in Allogenic Stem
Cell Transplant Patients
The purpose of this proposal is to detail a DNP Program Development and Evaluation
project that aims to reduce common complications and readmission rates of allogenic SCT
patients by providing transitional care management utilizing survivorship care plans (SCPs) at
an academic facility in Arkansas. This proposal will describe the incidence of readmissions
within an acute care setting and outpatient oncology clinic and its significance among the
allogenic SCT patients. Background information of SCTs and complications leading to 30-day
readmission to the hospital is described. Literature supports the use of SCPs to enhance
patient understanding of common complications post-transplantation and decrease
complications that lead to 30-day readmissions to the hospital. A non-randomized quasiexperiment design, consisting of pre-and post-intervention groups, will be used to evaluate
SCT efficacy. Lastly, project results highlight effectiveness of a SCP on 30-day readmission
rates, the extrapolation of results, and methods to promote project sustainability.
Background and Significance
Allogenic Stem Cell Transplantation
The first successful stem cell transplant performed by Dr. E. Donnall in Cooperstown,
New York in 1957, paved the way for over one million stem cell transplants executed worldwide
(Australian Cancer Research Foundation, 2020). A SCT is a medical procedure in which healthy
stem cells are used to replace defective bone marrow of patients with hematologic malignancies
such as multiple myeloma, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, acute myeloid
leukemia, neuroblastomas, germ cell tumors, amyloidosis, and autoimmune disorders including
systemic lupus erythematosus and systemic sclerosis (University of Michigan 2020; John
Hopkins Medicine, 2020). An allogenic SCT is a complex procedure with the possibility of
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complications encompassing bacterial and fungal infections, cytomegalovirus, bleeding, graft vs
host disease, interstitial pneumonitis, hepatic sinusoidal obstruction syndrome, graft failure,
mucositis, nausea, vomiting, diarrhea, secondary new cancers, infertility, and sexual dysfunction
(Bejanyan et al., 2015).
Over the last 50 years, more than one million SCTs have been performed worldwide with
more than 50,000 performed annually and approximately 40% of transplants being allogenic
SCTs (Hamdeh et al., 2016). According to the Health Resources and Service Administration
(2020), a total of 22,863 transplants were reported and performed in United States in 2017, with
approximately 60 % being allogenic SCTs (HRSA, 2020 & Levine Cancer Institute, 2017).
Males account for 60% of allogenic SCT cases. In the United States, the median ages for
patients undergoing allogenic SCTs are 45-70 years old, with Caucasian Americans accounting
for 67%, African Americans for 12%, and Hispanics for 11% for this patient population (Be The
Match, 2020).
In Arkansas, there is currently only one facility performing adult allogenic SCTs via
packed red blood cells (PRBCs) or bone marrow (UAMS, 2020). This center has been
performing SCTs since 1993 with the first allogenic transplant program beginning in 2015
(BeTheMatch, 2020). There were 43 allogenic SCTs performed among recipients ages 45-64
years of age in 2015-2017. The one-year survival rate for this facility is 70.2% which is above
the national rate of 57.1% (BeTheMatch, 2020).
Acute Myeloid Leukemia (AML). AML patients will be the primary cancer population
of focus for the implementation of a SCP during this DNP proposal. AML is a type of fastgrowing blood cancer that starts in the bone marrow, and quickly moves into the blood
(Leukemia & Lymphoma, 2020). This type of cancer sometimes spreads to other parts of the

7
body including the lymph nodes, liver, spleen, and central nervous system. AML is one of the
most common types of leukemia in older adults and accounts for 1% of all cancers (American
Cancer Society, 2020). AML is twice as likely to be diagnosed in men than women with the
average age of diagnosis occurring between 45-70 years of age (Tuberville, et al., 2014).
According to the American Cancer Society (2020), annually there are approximately 19,000 new
cases each year occurring in the United States with approximately 11,000 deaths related to this
diagnosis. An allogenic SCT is the most common type of curative treatment option performed
among AML patients (Mayo Clinic, 2020).
Human Leukocyte Antigen (HLA). Allogenic patients undergoing SCTs require blood
testing to assess human leukocyte antigen (HLA) typing (BeTheMatch, 2020). HLA are proteins
found on most cells in the body that recognize which cells belong to the patient and which are
foreign (BeTheMatch, 2020). HLA matching represents the most essential barrier among the
many elements that impact the outcome of SCTs (Tiercy, 2016). Closely matching the HLA of
the donor to that of the SCT recipient allows for the best outcome and lower risk of
complications post-transplantation. There are three types of HLA donors which include matched
related donor (MRD) where the HLA is identical, matched unrelated donor (MUD) donor where
the HLA is unrelated, and haploidentical transplant donor where the HLA is half-matched
(American Cancer Society, 2020). MRD is the most preferred donor source due to improved
clinical outcomes following transplantation, faster engraftment periods, and decreased cost of
hospitalization following an allogenic SCT (Negrin, 2020).
Conditioning Therapy. Prior to an allogenic SCT a patient must undergo conditioning
therapy which is composed of chemotherapy, radiation, or both. Conditioning therapy aims to
kill any remaining cancer cells in the SCT recipient’s body, make room for donor stem cells in
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the marrow spaces, and weaken the immune system of the SCT recipient in preparation to
receive the donor stem cells (Memorial Sloan Kettering Cancer Center, 2020). The intensity of
the conditioning therapy is an important factor and dependent on the patient’s condition and the
source of stem cells (Atilla, 2017). There are two types of conditioning chemotherapy treatments
that consist of myeloablative or nonmyeloablative. Myeloablative SCT conditioning regimen
consists of high doses of chemotherapy with or without radiation aiming to kill the cancer of the
SCT recipient. This type of regimen is used for patients that are below the age of 65 years of
age and have few to no comorbidities (Franciscan Health, 2020). Nonmyeloablative
conditioning regimen consists of lower doses of chemotherapy with or without radiation aiming
to weaken the immune system allowing the donor stem cells to take over and make a new
immune system that will fight the cancer. This type of transplant is reserved for patients with an
advanced age of 65 years or older or abnormalities in one of their organ systems that will not
allow the use of the myeloablative regimen (Franciscan Health, 2020). According to Atilla
(2017), the relapse and survival rates are similar with each of the conditioning therapies.
Transplantation Phases. The allogenic SCT process consists of five phases:
conditioning, transplant day to engraftment, engraftment until the day of discharge, early
convalescence, and late convalescence (Memorial Sloan Kettering Cancer Center, 2020).
Conditioning is phase one in which an allogenic SCT patient is admitted to the hospital and
begins conditioning therapy for the next seven days. Phase two consists of transplantation day
until engraftment which is when blood count recovery begins, usually during day 10 through 30.
Phase three consists of engraftment through the day of discharge (American Cancer Society
2020; Memorial Sloan Kettering Cancer Center, 2020). Early convalescence is phase four in
which blood counts are in the recovery period, but the immune system is weakened with a high-
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risk for infections occurring from discharge until one-year post-transplantation. Lastly, late
convalescence occurs one-year post transplantation and onward in which the immune system is
fully recovered (Memorial Sloan Kettering Cancer Center, 2020).
Hospitalization. According to Broder et al. (2017), allogenic SCTs are expensive
treatments and are among the top 10 procedures with the highest overall costs associated with
hospital inpatient services in the United States. Allogenic SCT hospital cost, increased by
approximately 85% from $694 million to $1.3 billion over the time period from 2004 to 2007
(Broder et al., 2017). The median days for hospitalization for an initial allogenic SCT are 31
days. The average cost for a SCT is approximately $203,206 with 75% contributing to early
costs (Ballen et al., 2015; Bars, 2018). Allogenic SCT patients who undergo high dose
conditioning chemotherapy regimens can have hospitalizations that span from days to months,
depending on the type of transplantation, reactions or complications experienced during the
hospitalization (Cleveland Clinic, 2019; University of Utah Cancer Institute, 2018). Due to the
medical complexities and multiple transition points associated with the SCT treatment, SCT
patients have a higher risk for hospital readmissions which can lead to life-threatening issues and
prolong recovery (Bejanyan et al., 2015).
According to Roswell Park Cancer Institute (2013), survival rates have drastically
improved due to advances in molecular mechanisms, adapted therapeutic conditioning
treatments, and the increased number of SCTs performed in patients 65 years of age or older
with nonmyeloablative conditioning therapies (Walter et al,2010; D’Souza et.al, 2017).
Allogenic SCT related mortality has decreased due to improved supportive care, better strategies
to prevent severe infections and the incorporation of nonmyeloablative conditioning protocols
(Henig & Zuckerman, 2014). Patients specifically with AML showed a significant survival rate
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increase from 85% to 94% with MRD, and 63% to 86% with MUD (Roswell Park Cancer
Institute, 2013).
Common complications
The most common complications may occur in the early post-transplant period
particularly in the first 30 days (BeTheMatch, 2020). Approximately 80% of SCT patients
experience nausea and 45% experience vomiting (Denson et al., 2020). Diarrhea is caused by
several distinctive factors with acute GVHD, infections, and mucositis being the most common.
Nausea, vomiting, and diarrhea may interfere with nutrition and the ability for the patient to take
oral medications (Hamdeh et al., 2016 & Negrin, 2020).
Long term complications after receiving an allogenic SCT include infertility problems
and sexual dysfunction. The overwhelming majority of allogenic SCT patients will experience
infertility (Virginia Cancer Institute, 2020). Infertility is a late adverse effect occurring after a
SCT and greatly affects quality of life in allogenic transplant survivors (Atilla et al.,2016).
Sexual dysfunction may be experienced by allogenic SCT patients one year after transplantation
with nearly half of men and women experiencing at least one physical sexual dysfunction during
that time (Noerskov, et al., 2016). Sexual dysfunction is frequently one of the most common
long-term issues following allogenic SCT. Treatments with allogenic SCTs are associated with
short-and long-term toxicities affecting sexual function due to the high-dose conditioning
regimen and gonadal function changes (Atilla et al., 2016). Long-term complications include
decreased libido, vaginal dryness, atrophy, and erectile dysfunction (Andreini, et al., 2017).
Infections. Hospital readmissions due to infections among allogenic SCT patients
usually occur within the first 30 days post-transplant (Kaur, et al., 2019; Shain et. al., 2016).
According to the American Cancer Society infections are common during the first six weeks
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until engraftment has occurred (American Cancer Society, 2020). Infections can be classified as
bacterial, viral, and fungal, with bacterial and viral infections being the most common (Kaur, et
al., 2019 & Sahin et al., 2016).
Bacterial Infections. Bacterial infections are among the chief complications of allogenic
SCT patients with the most frequent causes being bloodstream infections (BSI) and
gastrointestinal infection such as clostridium difficile infection (CDI) (Balletto & Mikulska,
2015). BSI affects approximately 20%-30% of allogenic SCT recipients with the incidence
highest during the pre-engraftment neutropenia phase (Balletto & Mikulska, 2015). CDI
frequently occurs in the early post-transplant period with the average time ranging from 3 days to
33 days after transplantation (Kaur, et al., 2019). A study conducted by Balleto & Mikulska
(2015), on allogenic SCT patients found that SCT recipients were affected nine times more often
with CDI than non-cancerous patients. The allogenic SCT patient population is at highest risk
for CDI in the acute care setting affecting 12.5% to 21.3% of allogenic SCT recipients (Kaur, et
al., 2019).
Cytomegalovirus infection (CMV). CMV is one of the most critical viral infectious
complications related to host immune recovery after an allogenic SCT (Cho et al., 2018). CMV
reactivation occurs in approximately 50% to 70% of patients who undergo allogeneic SCTs and
may be associated with a 50% mortality rate (Boeckh, 2017). This virus has a profound impact
on the immune system causing gastrointestinal disease, pneumonia, retinitis, encephalitis, and
end-stage organ disease (Boeckh, 2017; Lin & Liu, 2015). Research conducted by Schelfhout et
al. (2019), utilized a United States database to explore the impact of CMV on hospital services
following allogenic SCTs. This study found that CMV-related readmissions are profoundly
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greater by 30% and accrued higher hospital costs compared to any other 30-day readmission
complication.
Graft versus Host Disease (GvHD). GvHD is the most common and serious adverse
effect of allogenic SCT patients. It occurs when the transplanted stem cells are identified by the
patient’s body as a foreign entity and therefore are rejected (Be The Match, 2020). Acute GvHD
can develop within the first months after allogenic SCTs and occurs in 20% to 50% of patients
undergoing allogenic SCTs (Kaur et al., 2019; BMTinfo, 2020). The main systems affected by
GvHD are cardiovascular, pulmonary, integumentary, hepatic, and the gastrointestinal tract
(Leukemia & Bone Marrow Transplant Program, 2016). GvHD increases the risk of bacterial
and viral infectious complications such as CDI, CMV, and hepatic sinusoidal obstruction
syndrome and many patients suffering from GvHD die from these infectious complications
(Ghimire, et al., 2017).
Graft failure (GF). Engraftment is key to overall better health and long-term survival
and occurs within the first 30 days after transplantation (Hutt, 2017). Graft failure is defined as
the lack of hemopoietic stem cells following an allogenic SCT. According to a study conducted
by Madan et al. (2015), there was a positive correlation between disease type and graft failure.
Allogenic SCT patients with malignant disease had a three times higher incidence of GF than
those with non-malignant diseases. Patients with a MUD had a 20% higher probability of GF
than any other donor type.
Bleeding. Prolonged severe thrombocytopenia and tissue damage caused by high-dose
chemotherapy conditioning regimens lead to increased bleeding tendencies among allogenic SCT
patients (Labrador et al., 2015). According to Negrin (2020), bleeding occurs in approximately
one quarter of allogenic SCT recipients, with at least one bleeding episode occurring after
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transplantation. The most common and life-threatening bleeding problems in allogenic SCT
patients occur in the pulmonary and gastrointestinal systems (Labrador et al., 2015).
Acute Pulmonary Complications. Acute pulmonary complications, including
interstitial pneumonitis, pneumonia, pulmonary edema, and diffuse alveolar hemorrhage are
frequently fatal complications following allogenic SCTs affecting approximately 40-60% of
recipients. Acute pulmonary complications contribute to 50% of all deaths in allogenic SCT
patients (Pena et al., 2014).

Interstitial pneumonitis (IP) is characterized by widespread

alveolar injury in the absence of lower respiratory tract infection or fluid overload. IP develops
in up to 10% of allogenic SCT patients typically within four months after transplantation (Kaner
& Zappetti, 2018; Porter, 2017). IP results from a variety of lung insults, including high-dose
chemotherapy or radiation exposure and undiagnosed viral infections (Porter, 2017). The median
time of onset for IP is 15-65 days after allogenic SCTs (Porter, 2017). Pneumonia often occurs
in 15%-25% of allogenic SCT patients (Balletto & Mikulska, 2015). Pneumonia is depicted as
infection that causes inflammation of the air sacs in one or both lungs (MayoClinic, 2020).
According to Balletto & Mikulska (2015) the median time of pneumonia after transplantation
was 66.5 days with the mortality rate at 46%. Pulmonary edema results from fluid overload,
cardiac dysfunction secondary to chemotherapy, radiation therapy, and renal failure (Pena et al.,
2014). Pulmonary edema is a noninfectious complication with a peak incidence of 20% in the
second and third weeks after allogenic SCTs (Carreras & Cooke, 2018). Diffuse Alveolar
Hemorrhage (DAH) is a relevant cause of an acute pulmonary complication occurring in 2%14% of allogenic SCT patients. DAH has a median onset of 12-15 days within the first month
after allogenic SCTs (Pena et al., 2014; Carreras & Cooke, 2018). DAH has similar
characteristics to IP as it is caused by acute lung injuries, capillary bleeding induced by
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conditioning chemotherapy and radiation, and undiagnosed infections. DAH has a mortality rate
of 48% in this patient population (Carreras & Cooke, 2018; Soubani & Pandya, 2015).
Hepatic Sinusoidal Obstruction Syndrome (SOS). SOS, previously termed hepatic
veno-occlusive disease (VOD), is characterized by hepatomegaly, right upper quadrant
abdominal pain or fullness, jaundice, and ascites (Negrin & Bonis, 2019). Typically occurring in
the first two weeks after an allogenic SCT, the incidence of SOS typically ranges from 8% to
14% (Dalle & Giralt, 2016). The onset of SOS can be complicated by multiorgan disease
(MOD), characterized by pneumonia, kidney failure, liver damage and encephalopathy (Negrin
& Bonis, 2019; Virginia Cancer Institute, 2020). SOS is associated with a mortality rate greater
than 80% after allogenic SCTs (Dalle & Giralt, 2015; Negrin & Bonis, 2019;).
Oral Mucositis (OM). OM is part of a larger category of adverse effects of mucosal
barrier injury, which can include damage to the entire gastrointestinal mucosa (Chaudhry et al.,
2016). Oral mucositis is an inflammatory process of the oral mucosa ranging from mild
inflammation presenting as erythematous lesions to extensive ulcerations penetrating the
submucosa (Durlacher, et al., 2015). OM begins to develop within two to four days following
the completion of the high-dose conditioning therapy and occurs in 80%-100% of patients
undergoing allogenic SCTs (Chaudhry et al., 2016; Durlacher, et al., 2015). According to Berger
et al. (2018), the average cost of OM related to hospitalization among SCTs was between $10,
558 -$42, 749. Severe OM is considered one of the main determinants of cost in the early
transplantation period as it can result in pain, nutritional problems as a result of the inability to
eat, and increased risk of infections due to open sores in the mucosa prolonging inpatient
hospitalization and increase in hospital costs (Chaudhry et al., 2016; Negrin, 2020; The Oral
Cancer Foundation 2020).
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Secondary Cancer Occurrence. The success of allogenic SCTs had led to the
unfortunate complication of secondary malignancies after receiving high dose conditioning
therapy (Negrin, 2020). Risk factors for developing secondary tumors are genetic defects, high
dose-irradiation in the conditioning regimen, HLA mismatching of the donor/recipient, and
chronic GvHD. B-cell proliferative disorders (BCLD) is a secondary malignancy that has a 1%
incidence that can occur in the first year after an allogenic SCT (Camp et al., 2014). According
to Majhail et al. (2015), the occurrence of solid tumor cancers such as lung cancer are twice as
high in allogenic SCT patients.
30-day Readmission Rates.
The Centers for Medicare and Medicaid Services (CMS) uses 30-day unplanned
readmission rates under the Hospital Readmission Reduction Program as a standard to penalize
hospitals with high rates of readmissions for certain medical conditions (Dhakal, et al., 2019). In
2015, the Oncology Care Model was initiated by the CMS to help with the increasing health care
demands and cost of care for cancer patients. This model aims to provide quality care at the
same or lesser cost to susceptible patients such as allogenic SCT recipients with unplanned
readmissions due to common post-transplant complications.
Allogenic SCTs are associated with elevated costs related to 30-day readmissions for
post-transplantation complications resulting in prolonged hospitalizations and poor survival rates
(Broglie et al., 2019; Dhakal et al., 2019). According to Kaur et al. (2019), more than 50% of
readmissions among allogenic SCT patients occur within the first 30 days post-transplantation.
Patients with blood cancers, such as AML, generally have a higher rate of 30-day readmissions
related to transplantation complications such as infections at 43%, gastrointestinal symptoms at
12%, and neutropenic fever at 10% (Dhakal, Giri, & Levin, 2019). In a systematic review by
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Shahid et al. (2019), the median time for readmissions post allogenic SCT discharge was 22.5
days with the median length of stay at 12 days. A cohort study of patient data from the United
States Nationwide Readmission Database detailed the overall incidence of 30-day readmissions
was 24.4% among allogenic SCTs in United States hospitals (Seto et al., 2018; Levin, 2019 ).
Rauenzahn et al. (2015), conducted a cohort study on 91 patients undergoing an allogenic SCT
and found that 35 patients, 38%, were readmitted within 30 days of discharge, and were usually
affected by infection, fever, and GI issues.
30-day Readmission Risk Factors. According to Bejanyan (2012), risk factors that
affect 30-day readmissions, include myeloablative conditioning regimens with high-dose
radiation and infections occurring during the allogenic SCT. Springer et al. (2015), asserts that
30-day readmissions are most prevalent among older adults with a median age of 59 years, high
rates of infection during inpatient hospitalization, and prolonged initial hospital stay past 30 days
after an allogenic SCT. Rauenzahn et al. (2015), found that male gender and a diagnosis of
AML versus other cancers were all predictive risk factors for 30-day readmissions.
Survivorship Care Plans (SCPs)
The American Society of Clinical Oncology recommends that every survivor should
receive a SCP after allogenic SCTs (Rauenzahn et al., 2017). SCPs are documents that
summarize a patient’s cancer treatment and provide early follow-up directions and treatment
outlines to prevent and manage post-transplant health-related complications (Chaput, 2018;
Memorial Sloan Kettering Cancer Center, 2020). The urgency to incorporate survivorship
follow-up care by 2025 is important as the requirement for oncology services is expected to
outweigh the supply of cancer healthcare providers (Chaput, 2018). These documents are pivotal
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tools to aid in transition of care and facilitate communication between specialty providers and
primary care providers (Majhail et al., 2019; Oancea & Cheruvu, 2016).
Barriers to SCP Dissemination. Traditionally, primary care providers have been
uncomfortable managing the care of the increasing number of cancer survivors due to the lack of
awareness for how to identify and treat complications (Jacobsen et a., 2018). Rooij et al. (2017)
specified healthcare providers noticed poor prognosis was the key barrier with communicating
health concerns among allogenic SCT patients (Rooij et al., 2017). According to Birken et al.
(2018), concluded further barriers involved a lack of coordination among healthcare providers
resulting in omission of recommended services or a lengthy SCP with duplication of information
(Birken et al., 2018). Mayer et al. (2015), determined the shortage of oncology providers
resulted in providers not completing and delivering the SCPs post-treatment. In addition, this
study found the lack of a standardized format led to excessive time spent preparing SCPs.
Selove et al. (2016), deduced that poor support for survivors physical and emotional needs
attributed to major factors for SCP dissemination in post-treatment care.
Finally, socioeconomic status and age are other factors noted as contributable obstacles
to unsuccessful implementation of SCPs. Older adults tend to have a decreased ability to recall
information and people with lower socioeconomic status may have decreased health knowledge
and information delivery (Rooij, 2017). Klemanski et al. (2016), concluded that a shortage of
funding, inadequate access to care, and decreased information on utilizing reimbursement
opportunities for SCPs were all barriers to implementation.
Inconsistencies to SCP Dissemination
In clinical practice the implementation and dissemination of SCPs have been low to
inconsistent with only 10%-20% of oncologists providing a SCP after transplantation (Rooij et
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al., 2017; Klemanski, Browning, & Kue, 2016). According to Klemanski et al. (2016),
additional inconsistencies include the absence of reimbursement, formatting consensus, cost of
documentation, and sustainability. Many transplant facilities commonly underuse SCPs because
of inadequate resources or the shortage of evidence regarding the effectiveness on patient
outcomes (Majhail et al., 2019). According to Klemanski et al. (2016), the duties for composing
the survivor care plan were very time consuming for one person. Jacobsen et al. (2016), reported
other inconsistencies included patients being unsure of the benefits from receiving a SCP, the
design of a SCP for diverse populations, and people with low health knowledge.
Financial Implications of SCT
Allogenic SCT patients sometime experience financial problems associated with longterm recovery and complications after SCTs (Denzen et al., 2016). According to Broder et al.
(2017), the median cost for conditioning chemotherapy and 30-day readmission was $289, 283.
A retrospective survey among allogenic SCT patients found that 73% reported their sickness and
transplantation had a financial impact on their household with 47% reporting household income
was decreased by 50% (Khera et al., 2015). Many patients must relocate temporarily to be near a
SCT facility and must stay several weeks to months after transplantation (Abel et al., 2016).
This causes problems with transportation to appointments, travel expenses, and extended time
away from work. Financial difficulties can contribute to poor treatment adherence, higher levels
of stress, and poor overall health particularly among post allogenic SCT patients (Abet et al.,
2016).
In conclusion, common infectious complications after an allogenic SCT necessitate
readmissions within the first 30 days post transplantation (Cho et al., 2018). Allogenic cancer
survivors continue to be at risk for late complications that can cause considerable sickness and
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contribute to psychosocial and financial strains (Oancea & Cheruvu, 2016). Utilizing SCPs may
improve surveillance and coordination of care among healthcare providers and identify common
complications post transplantation, resulting in a reduction in 30-day readmissions.
Problem Statement
The problem statement for this DNP program development and evaluation project is that
allogenic SCT patients often experience hospital readmission rates within 30-days of discharge
due to complications post-transplantation. Providing allogenic SCT recipients with information
on preventative measures and the signs and symptoms of complications prior to hospital
discharge may improve patient reporting of adverse events. It is expected that these enhanced
understanding combined with close follow-up appointments and the frequent use of a SCP
questionnaire will increase patient familiarity of post-transplant care leading to reduced 30-day
readmission rates for allogenic SCT patients.
Purpose Statement
The purpose of this DNP program development and evaluation project is to decrease
hospital readmission rates that occur during the first 30 days after transplantation in allogenic
SCT patients at an academic hospital. Patients will gain evidence-based education on
preventative measures and common complications through the initiation of SCPs. The SCP
Questionnaire will be utilized during the discharge process and weekly in the outpatient clinic
follow-up visit to help improve the gap in care for common complications after transplantation.
PICOT Question
(P) In allogenic SCT patients, (I) how does the addition of a SCP, (C) compared to
current discharge practice, (O) effect 30-day readmission rates (T) within 10 weeks?
Needs Assessment of an Inpatient Facility in Pulaski County, Arkansas

20
Project Objectives
The objective of this needs assessment was to ascertain the gap in care, resulting in 30day readmission rates among allogenic SCT patients. A gap in care was identified by several
key stakeholders of an oncology team at an inpatient facility in Arkansas. These key
stakeholders wanted to identify barriers and conjure solutions to help improve patient health
outcomes.
Participants
The targeted contributors of this needs assessment were chosen as key stakeholders on
implementing a practice change among allogenic SCT patients. The head of the stem cell
transplant department is an essential component and overseer for this project. The clinical service
manager of the oncology unit, an Advanced Practice Registered Nurse (APRN) will help with
implementing change in the unit. The Director of Nursing will serve as resource and is a key
stakeholder for this project. Additional participants include the inpatient oncology staff and
oncologists. All stakeholders have provided insight on the gaps of care for allogenic SCT
patients and serve as site champions encouraging the implementation of to reduce common
complications and 30-day readmission rates post-transplantation.
Rationale of the Needs Assessment
Many patients at this academic facility are discharged with little education regarding
post-transplantation care after an allogenic SCT. Identifying gaps in care is crucial to address in
this population as it could decrease 30-day hospital readmissions and establish preventative
measures to improve patient knowledge of common post-transplant complications. The result of
the Needs Assessment will direct attention to the specific needs of the allogenic SCT population
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at this academic hospital, identifying gaps in current processes that result in readmission to the
hospital within 30 days.
Data Collection Tool
The Bone Marrow Needs Assessment questionnaire was given to the eight key
stakeholders to understand the needs that should be met when implementing this practice change
to oncology patients. The main objectives were to assess staff readiness and gather concepts and
ideas for a practice change. Eight open-ended questions were created and presented to the key
stakeholders with an open comment section left for any additional commentary. See Appendix
K for Needs Assessment survey.
Sample, Sample Size, and Sample Procedure
Convenience sampling was used to select the participants for this Needs assessment.
Participants were chosen based upon their degree of involvement in the care of oncology
patients. A total of eight interviews occurred, with eight-open-ended questions given to the
nursing staff and key stakeholders.
Implementation and Data Analysis
Each interview was conducted in a quiet setting in the unit’s conference room at the
hospital, for approximately 15-20 minutes on the afternoon of June 24, 2020. Clarification was
provided for all questions and promotion of ideas were offered to interviewers. Key findings
from the questionnaire included poor discharge processes, a lack of resources, workload demand,
poor patient education, and recurrent readmissions among allogenic SCT patients. All the key
stakeholders agreed that readmissions were a major concern and that education is not properly
provided to the patients and families. Many staff members expressed key barriers such as failure
to recognize high-risk patients, poor communication among staff, high workload demand, and
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ineffective discharge planning. All of the participants were willing and ready to participate in
the project. Support and advice were received from the key stakeholders during their interviews.
Many staff members recommended to employ a designated discharge nurse to ensure that every
patient was discharged appropriately and received patient education.
Through the use of the gathered information, contributing factors identified as gaps of
care were patient education, discharge processes, and readmissions at this inpatient facility. The
data collected will be used to address all concerns to establish a practice change for at this
inpatient facility. After evaluation of the Needs Assessment results, the project team will meet to
discuss health outcomes and possible barriers to change implementation.
Aim and Objectives
The aim of this DNP project was to utilize survivorship care plans for allogenic SCT
patients prior to hospital discharge in order to reduce 30-day readmission rates. There was not a
discharge education protocol in place to review common complications and preventative
measures for allogenic SCT patients. Following protocol implementation, this project expected
to reduce readmissions rates among allogenic patients by 50% by March 2021. The objectives
were as followed:
•

Improve patient understanding regarding common post-transplant complications and
preventative measures by 75% through the use of the SCP Questionnaire

•

Distribute survivorship care plans to 50% of allogenic SCT patients prior to discharge
from the hospital

•

During the initial outpatient follow-up visits, 100% of post allogenic SCT patient’s
education will be evaluated utilizing the SCPs with a questionnaire followed by repeating
the questionnaire weekly for three weeks.
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•

During the outpatient follow-up visits, 75% of allogenic SCT patients will complete the
full 4 weeks of post-discharge SCP Questionnaires.

•

Decrease 30-day readmission rates of allogenic SCT patients by 50%
Review of Literature
In order to gather background information about allogenic SCT patients and SCPs a

review of literature was conducted to find evidence-based information and research articles using
the key words allogenic, stem cell transplants, bone marrow transplant, survivor care plans,
common complications, infections, and graft versus host disease. A detailed search strategy was
conducted with Dr. Tony Stankus utilizing the following databases: CINAHL, PubMed, Google
Scholar, Web of Science, Bone Marrow Donor Program, and the American Cancer Society. The
search was limited to peer-reviewed articles and journals written between 2015-2020. Inclusion
criteria were studies that demonstrated impact of 30-day readmission rates, infection, bleeding,
graft vs host disease, interstitial pneumonitis, hepatic veno-occulsive disease, graft failure,
mucositis, nausea, vomiting, organ damage, relapse, secondary new cancers, abnormal growth of
lymphatic tissue, infertility, hormone changes in the thyroid and pituitary glands, cataracts, and
sexual dysfunction (American Cancer Society, 2020). Exclusion criteria included research more
than five years old, children less than eighteen and research that was not written in English.
Twenty articles were accepted after inclusion and exclusion criteria was applied. See Appendix
C for EMSON Evidence Table.

Survivorship Care Plans
Discharged patients after an allogenic SCT can experience a difficult transition as they
adjust to the new changes and expectations of their post-transplant life (Mars, 2018). SCPs are
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tools that improve communication between healthcare providers and patients and can ease
transitions from the acute care setting to the outpatient setting (Donohue et al., 2017). A SCP
has the ability to decrease distress by increasing the patient’s understanding of common
complications and evidence-based preventative measures (Denzen et al., 2019). In 2020, The
American College of Surgeons’ Commission on Cancer (ACos Coc) revised their 2016
accreditation standards requiring all cancer programs to deliver a SCP to 50% of survivors to
now only strongly recommending a SCP post-transplantation (Christensen, Agee, & Bellomo,
2020). The ACoc Coc’s amendment to the scope of standards in 2016 was due to only 21% of
cancer institutions meeting the accreditation standards.
SCP Components
A SCP is a detailed documentation given to a cancer survivor prior to discharge that is
tailored to included specific information pertinent to the patient’s type of cancer and
individualized treatment plan (National Cancer Institute, 2020). A SCP includes information
about the cancer diagnosis, conditioning regimen treatment with specific drug names, number of
dosages, number of cycles, along with radiation type, number of dosages, and surgical
procedures performed. The SCP follow-up plan should contain specific recommendations for
ongoing care that include a detailed schedule for oncology appointments, surveillance testing,
and identifying and managing long-term and late effects. Health promotional strategies may also
be included to provide information on comprehensive care for each body system, central catheter
care, smoking cessation, alcohol and dietary modifications, and regular weight-bearing exercises.
The oncology providers and the treatment facility’s contact information should be included in the
documentation. Lastly, Rooji et al. (2017), suggested including information to help meet the
emotional, social, legal, and financial needs of allogenic SCT survivors.
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Survivors Perception
The primary goals of a SCP are to improve health outcomes and enhance patient
knowledge of preventative measures and common post-transplant complications (American
Cancer Society, 2020). Seventy percent of cancer survivors reported expansion of knowledge
with the ability to manage their condition and side effects when an oncology healthcare provider
verbally explained their follow-up care and provided a copy of their SCP after their treatment
(Kenzik et al., 2016; Morken et al., 2019). According to Morken et al. (2019), 93% of survivors
reported receiving a paper copy was more effective than electronic copies at the end of their
transplantation and served as a reminder of follow-up appointments and provided education on
future complications (Morken, et al., 2019). Majhail et al. (2019), described 60% of survivors
reported satisfaction with their SCP and stated improved knowledge and understanding about
their cancer, treatment regimens, and follow-up care. According to Phillips et al. (2020), and
Brant et al. (2016), 70% of survivors were able to make better health care decisions which
improved their follow-up compliance and care coordination with their healthcare providers.
Provider Perception
Seventy percent of healthcare providers in a Canadian Wellness Cancer program
indicated that SCPs were helpful with increasing their own understanding of treatments given
and transplantation side effects (Caput, 2018). Kanagasundram & Amini, (2019), found that
86% of healthcare providers reported that SCPs integrated continuation of health, physical, and
physiological routines (Kanagasundram & Amini, 2019). According to Garcia et al. (2016), 70%
of clinicians were highly satisfied with the use of SCPs and shared positive attitudes towards
their usage and effectiveness on improved patient care (Brant et al., 2016; Garcia et al., 2016). A
study conducted by Blanch-Hartigan et al. (2015), found that 65% of healthcare providers
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reported they were more susceptible to discuss survivor care issues with patients that had
received SCPs when compared to those who did not. According to Stricker (2019), the use of
SCPs demonstrated improved provider knowledge of cancer disease, better surveillance among
healthcare providers, and better quality and coordination of care.
Implementation of SCP
As survivorship rates continue to increase and institutions aim to overcome impediments
to SCP compliance, it is valuable to work as a multidisciplinary team and employ the necessary
tools to ensure the distribution of SCPs (NextPath, 2020). Implementation of SCPs involves
organizational resources, adequate electronic systems, standardized templates, and in-service
training for SCP usage (Rooij, et al., 2017). In a systematic review performed by Birken et al.
(2018), several cancer programs successfully implemented a SCP plan of action by proactively
developing dedicated champions. This study also suggested the designated champions should be
responsible for generating, completing, and providing the SCP to patients at the end of
transplantation. Mayers et al. (2015) found that efficient implementation of SCPs can be
generated by a semi-automated system that recognizes the date the patient’s treatment ends,
efficient times to deliver the SCP at discharge, and create functions that could track usage. The
Centers for Disease Control and Prevention (CDC) has a Comprehensive Control Center
designed to support oncology providers with navigating through barriers with SCP
implementation. Oncologists are able to utilize the Comprehensive Control Center to receive
help with creating and evaluating SCPs in efforts to improve patient knowledge and outcomes on
common complications post-transplantation (CDC, 2019).
Effects of SCP
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According to Morkel et al. (2019), implementing SCPs into the electronic health record
(EHR), reduces time and resources needed to compile a SCP. SCPs can offer information on
financial resources which could reduce the likelihood of patients abandoning follow-up
appointments and financial distress among cancer patients (Thom et al., 2019). Coughlin &
Dean (2019), concluded financial material placed in the SCP could help provide guidance on
how to access institution-specific resources, public funds, and other charitable assistance
programs (Coughlin & Dean, 2019).
Prevention Strategies to Reduce 30-day Readmissions
Antibiotic and Antifungal Therapy
Infectious complications remain a clinical challenge for allogenic SCT patients especially
during the early phase after transplantation (Ullmann, 2016). The use of prophylactic antibiotics
during the pre-engraftment phase has been the gold standard of care during hospitalization over
the past 20 years (Horton et al, 2019). According to Aoun (2015), empiric therapy is vital as the
early detection of invasive infections is challenging and mortality is increased by 30% when
therapy is delayed. Antibiotic and antifungal prophylaxis therapy has demonstrated its ability to
reduce the incidence of severe complications resulting in readmissions by 5.6%. Lastly, Busca
& Pagano (2016), found prophylactic use of antifungal therapy medications reduced the risk of
infection by 4.1%.

Follow-Up Appointments
Follow-up appointments after the discharge process are an essential part of improving
patient outcomes and reducing 30-day readmission rates. Follow-up appointments allow for
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evaluation of diagnosis, adjusting and reconciling medications, and catching new incidental
complications after an allogenic SCT (Rockney & Dressler, 2019). In a systematic study
conducted by O’Marcondes et al. (2019), 30-day readmissions were reduced by 2% with prompt
follow-up appointments within a week of discharge. According to Jackson et al. (2015), followup appointments within 14 days after discharge was associated with a 19.1% reduction in 30-day
readmissions among high-risk allogenic SCT recipients. A study conducted by Mars (2018),
demonstrated that post-discharge follow-up telephone appointments within 72 hours are likewise
effective at reducing 30-day readmissions by 10% allowing healthcare providers to monitor for
common complications post-transplantation.
Post-Discharge Education
Patients with allogenic SCTs have unique health care needs and discharge educational
materials must prepare patients to safely manage their health care and medical complications at
home. Educational preparation throughout the patient’s hospitalization and especially at
discharge has the potential to reduce 30-day readmissions by 15% (Ridgeway, 2018). Healthcare
checklists have produced dramatic gains in patient safety and ensures that each healthcare
provider is presenting the same content to each patient and post-discharge information is
provided. According to Ali et al. (2018), post-discharge education should include information
about medications, infections and prevention tips, healthy eating, and signs and symptoms to
immediately report to the oncology healthcare team. According to Ridgeway (2018) postdischarge education should include tips on oral hygiene, skin management, venous access device
care, outpatient clinic routine, dehydration prevention, signs and symptoms to report, and
medication review. Both studies concluded that post-discharge education would provide
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essential information needed to continue safe and effective methods of care at home to postallogenic SCT patients (Ali et al., (2018); Ridgeway, (2018).
Survey Tools
The European Organization for the Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC-QLQ) was developed in 1996 by The European Organization for the
Research and Treatment of Cancer to assess quality of life in patients with various types of
cancer (Radisic, 2020). The EORTCQ-LQL 25 is an instrument used to assess perception and
satisfaction of cancer patients in regard to health-related quality of life information (Pinto et al.,
2014). This questionnaire consists of 22-item Likert-style questions with two open response
questions. The Likert scale can be used to measure the relative intensity of responses along a
range. The Likert-style questions utilize a 1 to 4 scale, with 1 rating as not at all, and with 4
rating as very much. These items assess the cancer recipient’s perception of characteristics
about their disease and treatment, and the satisfaction of the information received. The
EORTCQ-LQL 25 survey offered cancer patient the opportunity to explain if more or less
information should be received and the type of information that should be included in the
questionnaire.
According to Asadi-Lari et al. (2017) this questionnaire is a reliable and self-reported
instrument that can be used in any cross-cultural observation or intervention study. Asadi-Lari et
al. (2015) explained this questionnaire showed a relevancy and clarity at 86% and an overall
appropriateness at 94% with measuring the perception of information in cancer patients. This
questionnaire has been tested in large international and multicultural studies and is reliable and
applicable in cancer patients at different phases. The EORTCQ-LQL 25 questionnaire can be
applied in the daily clinical practice among all oncology patients with any disease type and
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treatment stage (Arraras, et al., 2016). The validity of the EORTCQ-LQL25 questionnaire can
be useful for baseline assessment and intervention measures to accommodate information
availability for patients upon discharge (Pinto, et al., 2015).
The Survivorship Care Plan (SCP) Questionnaire is an independently designed
questionnaire strictly used for the purpose of this project. The design of this questionnaire was
based on a study conducted by Hennell et al. (2004) on the development and validation of a
Patient Knowledge Questionnaire (PKA) for patients with early rheumatoid arthritis. The SCP
Questionnaire was developed to measure allogenic SCT patient’s knowledge on the education
provided at discharge on the components of their SCP. The SCP Questionnaire is comprised of
eight multichoice questions with a choice of four responses. Specifics areas from the
components of the SCP were identified for testing in the questionnaire which included: signs and
symptoms, drug therapy, monitoring, and preventative measures. Questions were written
without jargon or difficult terminology to aid in understanding (Hennell et al.,2004). In order to
prevent the possibility of certain responses consistently selected in error, questions were worded
in various ways (Hennell et al.,2004). This questionnaire will be used to assess knowledge
attainment before and after receiving a SCP.
In conclusion, the proposed DNP program development and evaluation project had a
strong foundation of evidence to support the need for the implementation of a SCP based on the
literature review. The review of literature highlighted the importance of compliance with the
implementation of a SCP to provide post-transplantation information on common complications
and preventative measures in the efforts to reduce 30-day readmission rates among allogenic
SCT patients. The evidence supported the need to use the EORTCQ-25 and SCP Questionnaire
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in order to assess knowledge and information received from the SCP and further accentuated the
need for the proposed DNP project.
Theoretical Framework
Lewin’s Change Theory
This DNP program development and evaluation project was designed to assess the effects
of a SCP on 30-day hospital readmission rates for allogenic SCT patients. The Change Theory
created by Lewin used the stage model with the founding three elements of unfreezing, change,
and refreezing (Petiprin, 2016). This theory best represented the guiding framework for this
program and development project as it provided a balance of driving forces and restraining
forces to guide implementation and created sustainable changes in this organizations. See
Appendix D.
Change Theory Concepts
The change theory had three major concepts analyzed to address possible barriers and
resistance to change: driving forces, restraining forces, and equilibrium (Petiprin, 2016). Force
field analysis, a strategic tool used to understand the necessary components for change, listed
benefits and challenges associated with the project’s innovation (Change Management Coach,
2015). This theory asserted that leadership roles have a strong presence in order to sustain a
positive change (Barrow et al., 2020). Involving stakeholders in change was a critical aspect of
planning for change, as it allowed for problem identification, goal setting, and action planning
which increased staff buy-in. The leading benefit from having stakeholders involved was the
ability to sustain change by cultivating an atmosphere of trust, open communication, and
collaborative participation (Weatherston, 2016).
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Driving Forces. Driving forces were those that pushed in a direction and caused a
change to occur (Petiprin, 2016). The change process was effective when commitment from the
key stakeholders was encouraged and a supportive environment was created to promote change.
One of the major driving forces for this project expressed by stakeholders was the need to reduce
30-day readmissions among allogenic SCT patients. Key stakeholders expressed their readiness
to participate in this project and were willing to help promote an environment that was conducive
to change and sustainability of this project.
Restraining Forces. Restraining forces were forces that countered driving forces and
hindered change because they pushed change in the opposite direction (Connelly, 2017). Staff
members communicated their readiness to help promote an improved environment. Many staff
members expressed this change was a necessitated component that helped to promote better
health outcomes for the allogenic SCT population. Many staff members expressed their
eagerness to help promote change by displayed excitement and welcomed a new adjustment.
There was some resistance unknown, as with any change. Resistance occurred among staff due
to loss of power, fear the unknown, failure, and a feeling of mistrust (Mdletye et al., 2015).
Further restraining forces among staff included proving change was not needed or poor timing
for change. This PI promoted reassurance to staff members, communicated change effectively,
implemented change in several steps, and provided support to those who were resistant to face
those unexpected challenges,
Equilibrium. Equilibrium is a key concept of modern science (Scandizzo, 2019).
Equilibrium can be raised or lowered by changes that occur between the driving and restraining
forces (Nursing Theories, 2017). Complex adaptive systems require equilibrium in order to
maintain and survive an ever-changing environment (Wojeciechowski et al., 2016). There were

33
currently no interventions put in place to help reduce 30-day readmission rates of discharged
allogenic SCT patients, so the implementation of this project improved health care outcomes.
The results of this DNP project were used to establish and support the incorporation of this new
practice change. The key stakeholders’ involvement in the planning and implementation phase
were essential to building a strong foundation to sustain the change after the project
implementation ended. Once the results of the program were analyzed, the key stakeholders
were the principal constituents that devised a plan for sustainability (Wojeciechowski et al.,
2016).
Lewin’s Change Theory Stages
Stage One: Unfreezing. This was the first stage in which understanding change is
needed to help improve 30-day readmission rates (Barrow et al., 2020). A needs assessment was
conducted to determine barriers for readmissions. Key stakeholders and oncology registered
nurses (RNs) expressed the need to implement a project that addressed readmission
complications and preventative measures. Through the data collected from the needs assessment
a SCP was deemed to be a resourceful tool that could be given to each patient and families to
assist in increasing knowledge and understanding for preventative measures and complications
post-transplantation.
This principle investigator (PI) provided a training PowerPoint presentation during a
scheduled meeting in October 2020 to inpatient oncology RNs and key stakeholders. This
PowerPoint presentation included the SCP components, SCP Questionnaire, and the aim and
objectives for this project in the efforts to reduce readmissions. Inpatient in-service meetings
occurred during the week of implementation of this project to aid as refresher sessions and
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provided script training to each oncology RN to follow when dispersing the SCP Questionnaire
and SCP material during discharge.
A prearranged meeting in October 2020 was conducted in the outpatient oncology clinic
that included the transplant coordinator, RNs, advanced practice registered nurses (APRNs), and
oncologist. This meeting consisted of a PowerPoint presentation that described the
modifications occurring inpatient, the SCP components, and the SCP Questionnaire. A copy of
the SCP and a SCP Questionnaire was given to each of the APRNs and oncology doctors to
familiarize themselves and review the components of each document.
This PI reviewed the goals with the APRNs and oncologist to emphasize how the SCP
and follow-up SCP Questionnaire would potentially aid in improving patient knowledge and
understanding on preventative measures and complications post-transplantation. This PI
requested that each of the APRNs and oncologists distribute the EORTC-QLQ 25 at the initial
visit only and redistribute the SCP Questionnaire during the initial visit and weekly for two
weeks with each discharged allogenic SCT patients. This PI was present in the outpatient clinic
to monitor the dispersal of both the EORTC-QLQ 25 and the SCP Questionnaire during the first
two weeks to ensure implementation was transitioning correctly.
This PI was available to both the inpatient and outpatient sites to help with answering
questions and clarify the process occurring. Lastly, stakeholders and trained oncology RNs were
able to provide input during this stage to address any resistance or developments that needed to
occur prior to implementing the change.
Stage Two: Change. The method of initiating the change process occurred during stage
two which was for implementing new practices. Project implementation began in January 2021
and continued through March 2021. An initial SCP Questionnaire assessed the preliminary
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patient understanding of preventative measures and complications distributed by this PI or the
trained oncology RN prior to the patient receiving a SCP. Afterwards, a SCP, was reviewed with
the patient and family by this PI or a trained oncology RN. This PI was available to evaluate the
inpatient oncology RN’s discharge education. A biweekly contest in the inpatient setting was
promoted to remind and ensure oncology RNs about implementation of this new change.
During the initial outpatient clinic visit the EORTCQ-LQL 25 was dispersed by this PI,
or trained APRN to assess the patient’s perception and satisfaction with information received in
regard to their cancer treatment and care. The redistribution of the SCP Questionnaire was given
during the first initial visit and weekly for two weeks, by this PI, and a trained outpatient APRN,
to assess the patient’s retention of knowledge from the components of the SCP. This PI was
available to aid with incorporating the EORTCQ-LQL 25 and the SCP Questionnaire during the
initial visit with the APRNs. This PI monitored the distribution of the EORTCQ-LQL 25 and
follow-up SCP Questionnaires by the APRNs. The SCP Questionnaire were collected and
evaluated to assess if there was a differentiation of scores from discharge, the initial outpatient
visit, and the two weekly visits.
Through the use of the plan-do-study-act (PDSA) cycle, this process was evaluated to
help correct deviations seen with the implementation process. The PDSA was used to evaluate
staff process, scheduling of appointments, patient calls received and returned, patients’
attendance to appointments, and weekly missed appointments by patients. Data was collected
and evaluated on the allogenic SCT patient’s willingness to accept the SCP at discharge and
willingness to participate with the EORTCQ-LQL 25 and follow-up SCP Questionnaire in the
outpatient setting. This PI tracked complications and necessary interventions that occurred
during the first 30-days post-transplantation. The length of stay was followed to evaluate how

36
long the patient was hospitalized related to the readmitting complication. This information was
dispersed weekly to both the inpatient setting and outpatient clinic to show the percentage of
readmissions occurring during this project.
Support and encouragement were provided to the staff by this PI regarding how the
change was impacting patient care and outcomes. This PI continued to aid and educate those who
were resistant by communicating the need for change and the benefits of decreasing
readmissions for this patient population. This PI promoted engagement from the key
stakeholders by emphasizing their presence and support during the implementation stage to help
encourage those who are resistant.
Stage Three: Refreezing. In this final stage of refreezing in Lewin’s Change Theory brought
about establishing a new status quo (Barrow et al., 2020). Leadership key stakeholders were
critical for this stage to help sustain and reinforce this new change in everyday practice. The
efforts of this program would demonstrate the benefits of SCPs and the SCP Questionnaire on
improving patient knowledge of post-transplant complications and preventative measures. The
results of the project will be disseminated to the key stakeholders, in hopes of gaining support to
implement a permanent discharge policy with SCPs.
Summary
Lewin’s Change Theory was used to implement a program development and evaluation
project to promote the distribution of SCPs prior to discharge and a follow-up SCP Questionnaire
in the outpatient oncology clinic to allogenic SCT patients. It was expected that patient
knowledge would improve by providing education on common complications and preventative
measures with the SCP and follow-up SCP Questionnaire. Thirty-day readmission rates would
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be decreased, and the sustainability of the program would continue after the implementation
phase.
Methodology
Project Description
Utilizing a SCP was a logical approach to educate patients prior to discharge and was
expected to decrease 30-day readmission rates among allogenic SCT recipients. The project took
place in the inpatient bone marrow unit and outpatient oncology clinic at an academic hospital in
Arkansas. The project included a retrospective chart review to determine diagnoses for 30-day
readmissions among allogenic SCT patients. Staff participation were assessed by analyzing the
charts and ensuring that all allogenic SCT patients received a SCP.
Project Design
The proposed DNP project was aimed to decrease 30-day readmissions among allogenic
SCT patients by utilizing a SCP. The approach of this project was a quasi-experiment design
with a pre-intervention group and a post-intervention group that were non-randomized. The preintervention group consisted of patients that were discharged prior to the implementation of the
new SCP program. The post-intervention group included patients that received SCPs at
discharge and the follow-up SCP Questionnaire during outpatient visits. The outcomes
measured included 30-day readmissions diagnoses, demographic data, and the number of
patients discharged after allogenic SCTs, and education retention.
Setting
The setting for this program and evaluation project took place at an urban academic
hospital in Arkansas. This facility housed 450 acute care beds, with more than 10,000
employees in 73 of the 75 counties in Arkansas (UAMS, 2020). This hospital was the only

38
Level One adult trauma center in Arkansas. This was the only adult allogenic SCT program for
the state of Arkansas. The outpatient oncology clinic was the second setting utilized for this
project. The outpatient oncology clinic was also a part of the urban academic facility located in
Arkansas and managed over 300 patients. The clinic was composed of seven medical
hematologists/oncologists that treated blood-related diseases, sickle cell disease, thalassemia,
leukemias and lymphomas, as well as cancers of other organs (UAMS, 2020).
Study Population
The study population for this project consisted of all patients undergoing allogenic SCTs
during the 10-week implementation period. All participating allogenic SCT patients received a
SCP prior to discharge. Family members and caregivers were involved for mentally incompetent
and non-English patients undergoing allogenic SCTs.
Study Interventions
The trained oncology RNs reviewed the SCP with patients in the inpatient setting prior to
discharge. The trained APRNs redistributed and conducted follow-up SCP Questionnaires
during the first outpatient visit and once weekly for two weeks in the outpatient clinic. The
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire
25 (EORTCQ-QLQ25) was administered during the initial outpatient oncology clinic visit to
assess patient satisfaction and perception of their cancer treatment and care.
Pre-Implementation Phase. This PI introduced this upcoming DNP program and
development project during a daily in-service meeting in October 2020, to inpatient oncology
RN’s and key stakeholders. A video PowerPoint was recorded to highlight the important
components from the in-service to disperse via email to those who were unable to attend the inserve. The in-service meeting prepared them for the process change that would occur over the
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next three months with this program. This PI met with the outpatient oncology clinic coordinator
to schedule a time and date for the month of October that was convenient for the APRNs to
discuss the changes occurring on the inpatient bone marrow
The SCP was constructed by this PI to provide education on evidence-based preventative
measures and materials on common complications. This PI met with the key stakeholders to
review and approve the components of the SCP prior to the implementation of this DNP project.
The creation of a SCP Questionnaire was created during this stage with the help of this PI’s
committee chairperson. This questionnaire was constructed with questions that assessed
knowledge and information contained in the SCP. A consent transcript was created by this PI to
serve as a guideline for trained oncology RNs to use during the admission process. The scripted
consent transcript detailed the aim and objectives of this project in preparation of obtaining a
signed consent from allogenic SCT patients participating in this project. This PI also constructed
a discharge scripted transcript as a reference for the delivery of the SCP Questionnaire and the
SCP during the discharge process. Lastly, this PI met the last week in October 2020 with an
academic institution statistical graduate student to help with formulating the excel codebook.
The codebook consisted of information to help collect data from the chart reviews, demographic
information, and compile project results.
Implementation Phase. The PI monitored the SCP distribution of the trained oncology
nurses’ practice during this stage and provided weekly updates on the implementation rates and
detection of potential complications that were identified using the SCP. This PI provided a chart
to aid in visual data on the percentage of SCPs dispersed each week by those implementing
SCPs. Through the use of the PDSA cycle, the PI monitored discrepancies and intervened when
necessary to keep the program on track. Readmissions and diagnosis were monitored and
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collected weekly for the allogenic SCT patients. Patient knowledge was monitored to assess if
improvements were made weekly with the redistribution of the SCP Questionnaires in the
outpatient clinic.
Post-Implementation Phase. This information was used to analyze and evaluate if 30day readmissions rates among allogenic SCT patients were decreased with the implementation of
this program development project. Data showed the negative correlation between an increase in
patient knowledge of preventative measures through SCPs and a decrease in 30-day readmissions
rates. The results of the project were disseminated to the facility’s key stakeholders, the
inpatient bone marrow unit, the outpatient oncology clinic, the academic facility, and the Eleanor
Mann School of Nursing.
Study Measures
Conceptual Definitions. The conceptual definition of the term 30-day readmission
referred to a discharge that occurs within 30 days of initial admission. The conceptual definition
of the term readmission referred to a discharge that occurs after a preliminary admission. The
conceptual definition of the term post-transplantation patient knowledge referred to a measure of
patient understanding of preventative measures and potential complications post-discharge.
Operational Definitions. The operational definition of the term 30-day readmission was
described as a discharge that occurred within 30 days of initial admission for an allogenic SCT.
Readmissions were measured by conducting chart reviews to determine the number of patients
readmitted for common complications. The operational definition of the term posttransplantation patient knowledge was information retained from the SCP during the discharge
process such as preventative measures and common complications. This information was
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analyzed using the SCP Questionnaire an instrument used to evaluate patient retention of
information from the SCP
Outcome Measures
The outcomes measures for this DNP program and development project were used to
evaluate the effect of the executed program and development change (MeInky & FineoutOverhold, 2015). A retrospective chart review was performed at the clinical site to gather data
on the number of patients with complications within 30 days post-discharge and the
differentiation of diagnoses. Outcome measures accessed the effect of the SCP on patient health
outcomes. The number of patients in the bone marrow transplant unit and the number of those
who were discharged were monitored. The number of SCPs reviewed at discharge were
measured. Patients completed the SCP Questionnaire prior to receiving the SCP and that score
was entered into the codebook.
Data was collected on the interventions in the outpatient clinic to prevent deterioration
after complications were identified. Chart reviews were used to determine if the protocol
implementation led to a decrease in 30-day readmissions through the use of the SCPs. The chart
review assessed demographic data, including gender, age, socioeconomic level, education level,
insurance, marital status: number of readmissions; readmission diagnoses; complications treated;
length of stay with readmission. Additional measures included the number of attended visits per
patients, the SCP Questionnaire score at initial visit and once weekly for two weeks, number of
telephone calls from patients who had questions about recovery, number of missed appointments,
number of patients with complications within 30 days of discharge, differentiation of
complication diagnoses, and interventions implemented to prevent readmission. If patients did
not keep their outpatient oncology appointment, this PI would call them to review the SCP
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Questionnaire with them. Outcomes measures compared pre-and post-implementation
information to conclude the project’s impact.
Process Measures
There was no current practice benchmark at this facility with SCPs; however, The
American College of Surgeons’ Commission on Cancer recommended that 50% or more SCPs
be distributed, so the process measures for this project was to achieve 50% of SCP distribution at
the time of discharge (Bell et al., 2017). Process compliance was monitored weekly by this PI.
Other process measures included the percentage of patients who completed the SCP
Questionnaire at the initial visit and then once weekly for two weeks with the goal of 75% of
patients to complete the SCP Questionnaire at each point in time.
Balancing Measures
Balancing measures of this DNP project were used to assess both positive and negative
outcomes of the implementation process. Balancing measures for this DNP project included the
number of readmissions, length of stay after readmission, and costs associated with readmission
and hospitalization. The current 30-day readmission cost for this clinical facility was unknown,
but a cost analysis was completed for the 30-day readmissions post-implementation.
Benefits/Risks
Benefits of this DNP program included the application of an evidence-based practice
intervention through the use of SCPs prior to discharge to improve patient knowledge of
preventative measures and common complications. There was minimal potential for emotional
or psychological strain when this PI or oncology RN reviewed the SCP with the patient. The risk
of these harms was minimized by providing a private atmosphere during the discharge process
and SCP instructions. This PI took all the necessary precautions to decrease the loss of
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confidentiality and patient’s privacy. Oncology RNs were well-informed on the importance of
providing an open pathway for communication with patients during the discharge and SCP
instructions. There were no suspected economic risks of harm related to the study intervention.
Subject Recruitment
The subjects were recruited and consented by purposive sampling on all allogenic SCT
patients admitted for transplantation by this PI, site champion, or a trained oncology RN during
the admission process to explain the project’s purpose, procedures, risk, benefits, and
confidentiality. All direct oncology RNs were trained prior to project implementation by this PI.
Consent Procedures
This DNP program development and evaluation project obtained consent from all
allogenic SCT patients participating in this project. All patients that met inclusion criteria for an
allogenic SCT were consented by this PI, site champion, or a trained oncology RN during the
admission process to explain the project purpose, procedures, risks, benefits, and confidentiality.
See Appendix N for Informed Consent Form.
Subject Costs and Compensation
Allogenic SCT participants did not receive cost or compensation for taking part in this
project. The two top performing oncology RNs were rewarded with gift cards for their
participation in this project.
Project Timeline
The project implementation began January 13, 2021 and ended March 27, 2021. Data
was collected and evaluated from late-February 2021 through March 2021. April 2021, the
findings from the data analysis was disseminated to the academic facility. See Appendix T for
Project Timeline.
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Resources Needed and Economic Considerations
The discharge program was not associated with any cost to the participants of the project.
The resources used for this project required paper, ink, staples, and two gift cards which all
expenses were paid out of pocket by this PI with the approximate cost of $75.

Implementation
The implementation phase of this project was planned and applied by all stakeholders and
team members; however, modifications to the interventions were necessary during the course of
this project despite the meticulous planning efforts. Plan, Do, Study, Act (PDSA) cycles were
utilized to analyze the implementation process and in-service meetings were scheduled to discuss
processes, outcomes, and balancing measures to ensure that complications were addressed during
the implementation process. The following discusses the implementation process, PDSA cycles,
deviations from the project’s timeline, and the current process flow during the implementation
process.
Implementation Process
While awaiting Independent Review Board (IRB) approval, this PI created a PowerPoint
presentation to present to the inpatient Registered Nurses (RNs) and Advanced Practice
Registered Nurses (APRNs). A meeting with the oncology Clinical Service Manager (CSM) and
Advanced Practice Partner (APP) of the bone marrow unit discussed their cooperation and
support to promote adherence with the implementation process. IRB approval was obtained on
Monday, January 11, 2021, with the implementation process beginning on Tuesday, January 12,
2021.
Nursing Education
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After IRB approval, the initial intervention occurred with nursing staff education. Four
30-minute in-service project training meetings were conducted during the same week of IRB
approval. Training sessions were on Tuesday, January 12, 2021, and Thursday, January 14, 2021
at 2:oo pm CST. A third session was held on Friday, January 15, 2021 at 4:00 pm CST to
include the night and weekend staff nurses. The final session was on Monday, January 18, 2021
at 2:00 pm CST in the outpatient clinic with the APRNs. All nurses and APRNs attended the
training sessions with a sign in sheet provided to account for each nurse and APRN.
Each nurse and APRN received all components of the project which included scripted
pre-and post-transplant letters, SCP Questionnaire, EORTC-QLQ 25, and the discharge SCP
educational material. The pre-transplant script contained a brief description of this PI contact
information, history of the transplant program, the purpose of the project, and expectations prior
to discharge. See Appendix L. The post-transplantation script contained instructions on
completing the SCP Questionnaire prior to discharge, the components of the SCP, and a section
that thanked the patients for participating in this DNP project. See Appendix M.
The SCP educational material consisted of a ten-page packet that included a welcome
letter to the SCP participant that detailed the materials of the packet. A personalized and
customizable treatment summary sheet with specific information pertaining to the patient’s
cancer diagnosis, transplant type information, chemotherapy drugs or radiation treatment used,
along with the transplant center’s contact information was included. Two pages of
recommendations for preventative care for each of the body systems, as well as information
about central catheter line care was provided. A two-page compilation of common
complications post-transplantation with signs and symptoms was incorporated. A list of
commonly used post-transplant medications described by name, drug type, usage, and side
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effects were included as a reference sheet. Lastly, the final two pages consisted of activities of
daily living tips and suggestions for discharging from the hospital. See Appendix I for SCP
Patient Education Material Packet.
The other components of the project included the SCP Questionnaire which consisted of
eight questions that inquired knowledge of post-transplant care, preventative measures, and
scenarios of when to contact their oncologist. See Appendix J for SCP Questionnaire. The
EORTC-QLQ 25 questionnaire consisted of nine questions that inquired information received on
aspects of their disease and treatment and an open commentary section. See Appendix K for
EORTC-QLQ 25.
In-service meetings reviewed the purpose and tentative objectives along with the
importance of gaining consent for each of the participants taking part in this project. Time was
allotted for questions about the project and the project’s components after each in-service
meeting. A detailed reminder email was sent with instructions for the project, each of the
aforementioned project documents, along with a PowerPoint Presentation, to every inpatient
nurse on the bone marrow transplant unit, the CSM, the APP, and the outpatient clinic APRNs to
use as a reference. All of the project’s consent forms, SCP Questionnaires, and discharge SCP
education materials were located at the central nurse’s station for easy access. This PI accepted
new participants into the Survivorship Care Plan program after the completion of the initial inservice meeting. The official start date for acceptance of new stem cell transplant participants
into this project was Wednesday, January 13, 2021.
Accepting Stem Cell Transplant Participants
On January 13, 2021, the project’s first allogenic SCT patient elected to participate in the
program. The inpatient nursing staff notified this PI the day of the patient’s admission. The
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following day, this PI discussed the objectives, risks, and benefits of participation in the project.
After receiving verbal feedback about all the components of the project, the consent form was
reviewed and signed. Three additional patients were admitted for their allogenic stem cell
transplantation and were consented by this PI during the dates of January 13, 2021 through
January 21, 2021.
Four additional patients were admitted undergoing their allogenic stem cell
transplantation and were consented by this PI and nursing staff during the dates of February 3,
2021 through February 12, 2021.
Three final patients were admitted undergoing their allogenic stem cell transplantation
and were consented by the oncology nurses during the dates of February 23, 2021 through March
5, 2021.
An educational session was provided explaining the expectations for discharge day and
the following three weeks after discharge. This PI explained to each participant that an eight
question SCP Questionnaire would be dispersed prior to discharge from the hospital and will
assess baseline knowledge of common complications and preventative measures associated with
allogenic stem-cell transplantation recovery. After the completion of the SCP Questionnaire, the
discharge SCP education material was distributed to them for post-transplantation care. After
reviewing all components of the project, this PI answered questions to ensure understanding
from each participant who signed the consent form. The time spent with each patient was
approximately 45 minutes after reviewing all project objectives, the educational discussion,
interventions upon discharge, and the question-answer period.
The first two consented patients were administered the SCP questionnaires by this PI
approximately four weeks after implementation. Each participant had an opportunity to ask
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questions about self-care after completing the questionnaire and received their discharge SCP
educational material. Participants were discharged on the same day following the completion of
the questionnaire.
Participants’ knowledge about their disease, treatment, and recovery concerns were
assessed using the EORTC-QLQ 25 during the initial follow-up outpatient appointment.
Knowledge attainment was reassessed during the initial visit with the redistribution of the SCP
Questionnaire. Reassessment of knowledge attainment continued weekly during outpatient
clinic visits for the next two weeks through the use of the SCP Questionnaire by the APRNs.
Monitoring of Participants
This PI attended weekly in-person chat meetings from February 1, 2021 through March
22, 2021 with the oncologists, bone marrow CSM, bone marrow APP, and other health
professionals to assess and discuss each of the allogenic patient’s current health status and
anticipated discharge dates. An email was sent after each meeting to the nursing staff and
APRNs to notify them of the patients to discharge for the upcoming week.
This PI met with each of the patients to reinforce expectations at discharge with the SCP
Questionnaire and thereafter approximately 14 to 21 days post-transplantation. Each of the
meetings ended with a question or commentary section to ensure patients concerns were voiced
and answered.
This PI collected SCP Questionnaires and EORTC-QLQ 25 weekly from both outpatient
and inpatient settings and entered the data into an excel spreadsheet. Chart reviews were
performed from February 5, 2021 through March 20, 2021 by this PI to monitor 30-day
readmissions post-transplantation. This PI found no 30-day readmissions among the participants
due to the implementation of interventions to deter readmissions to the hospital such as ordering
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blood products, intravenous fluids, and electrolyte replacement related to the post-transplantation
recovery phase and routine labs drawn to monitor post-transplantation care.
Weekly emails between this PI, transplant coordinator, and the outpatient APRNs
occurred to assess for missed appointments post-transplantation. Missed appointments during
the implementation phase were due to closure of the clinic related to inclement weather.
Reviewing Processes and Measures
Data collection was updated weekly throughout the course of this project upon gaining
consent from the participants. Paper copies of data were stored in a secured locked cabinet with
only this PI having access. Electronic copies of data were secured within the project’s
implementation site encrypted secure network.
Inpatient weekly meetings occurred over a 10-week span beginning January 18, 2021
through March 24, 2021. An initial meeting was held for inpatient RNs, CSM, and APP to meet
and review the project’s progress on February 2, 2021. This meeting prepared the staff for the
discharge protocol and review the process measure to distribute a SCP to all discharging patients.
The next meeting occurred February 3, 2021 to discuss the same measures with the outpatient
clinic APRNs as patients would continue to receive the SCP and EORTC-QLQ 25 in the
outpatient setting. The next meeting held approximately two weeks later in the outpatient setting
discussed balancing measures to decrease hospital cost by initiation of interventions to reduce
hospitals readmissions. The last meeting occurred on March 17, 2021 reviewed the outcome
measures of collecting the final completed questionnaires, collecting missing data on returned
phone calls made by APRNs, and assessed if readmissions occurred since the previous meeting.
Timeline Variations
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The initial project timeline varied when compared to the actual planned goals. The IRB
process began mid-October 2020 with several revisions made to the SCP proposal. The IRB
committee approved the protocol on January 11, 2021 and the SCT project implementation
period began from January 13, 2021 until March 26, 2021. See Appendix S for Final Gantt
Chart. The consenting period of allogenic SCT ended approximately two weeks early on March
7, 2021. Ending the consenting period early was necessary as allogenic stem cell transplant
patients are typically hospitalized for 30 days post transplantation. The collection of data after
March 27, 2021 would run the risk of not being included in the final results of the project. The
projected number of participants needed for this study was not met by March 7, 2021 as time
constraints were a determining factor. Project enrollment was a continuous effort as patients
were admitted at various times throughout the project for their allogenic SCT. See Appendix R
for Implementation Timeline.
PDSA Cycles
Inpatient Staff and Consenting. This PI noted after admitting the first two participants
for this project that patients consent forms were not completed. This PI investigated and met
with each patient that was admitted, but not consented. Patients reported information was given
about the project during the admission process, but no consent form was received. Clarification
about consent forms were answered by this PI during a weekly in-service meeting with the
nursing staff. Staff expressed their uncertainties of when consents forms should be signed during
the project. This PI reinforced that consents should be signed within 72 hours of admission.
This PI designated a central location for all nurses to place the signed consents in a folder for this
PI to pick up weekly and assessed the admission process for the next several weeks and noted
that all admitted patients for the remainder of the project had signed consents.
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Decreased Nurse Participation. This PI found low nurse participation during the first
four weeks of implementation, in which eight of the 22 nurses obtained consents. At a weekly
meeting this PI announced there would be a contest for two ten-dollar gift cards for the top two
nurses with the most consents during February 5, 2021 through February 13, 2021. This PI
announced the two winners the following week at the next meeting. After the implementation of
the promoted incentive, this PI assessed that all admitted patients were consented and 18 of the
22 nurses sustained obtaining consents throughout the remainder of the project. The four nurses
not accounted where out on maternity leave and family medical leave. This PI continued to
provide support and praise while monitoring the project weekly for interventions to be
implemented. Each week during the 30-minute in-service meetings this PI reviewed the number
of patients discharging each week, patients that received the SCP Questionnaires and discharge
SCP Questionnaire educational materials, and interventions needed to continue implementation.
Improved Discharge Education. The first consented allogenic SCT patient was
prepared to discharge after four weeks of implementation. After week five of implementation
the following patients noted complications in the discharge process such as decreased ability to
focus, time constraints, and nurses not reviewing educational material. Two ten-minute meetings
occurred on February 9, 2021 at 9:00pm CST and February 10, 2021 at 8:00pm CST to discuss
the implementation of the SCP questionnaires the night prior to discharge to ensure adequate
time for completion and proper review of the SCP educational material. Both in-service
meetings occurred as planned with 17 of the 22 employed night shift nursing staff attending the
meetings. This PI met individually with the remaining nursing staff unable to attend the inservice meetings. This PI monitored the new intervention of implementing the SCP
Questionnaire at night through returned demonstration among the night shift nursing staff. An
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increase in the discharge SCP Questionnaire scores improved by the increased number of correct
answers noted after administering during the night. This PI found that all patients received SCPs
and education for the remainder of the project implementing the SCP Questionnaires at night.
Outpatient Follow-up Appointments. This PI met with the outpatient clinic on
February 4, 2021 to reinforce the correct implementation of the SCP Questionnaire and the
EORTC-QLQ 25 at the initial visit and only the SCP Questionnaire weekly for two weeks as the
first patient was scheduled to discharge the next day. Time constraints were noted with the
application of the SCP and EORTC-QLQ 25 questionnaire after one week of monitored visits in
the outpatient setting. An in-person meeting was conducted with the APRNs to determine the
optimal time to implement the questionnaires. This PI and APRNs found that filling out the
questionnaires in the waiting area was more effective to decrease time constraints. The APRNs
agreed to having a designated area at the front desk with a copy of the questionnaires and a list of
the participants each week to ensure patients receive and fill out their questionnaires at check-in
while waiting. APRNs would collect the completed questionnaires during their visit with each
participant and placed the completed surveys in the designated area for pick up. After the
implementation of this intervention APRNs verbally reported that patients were not rushing to
fill out surveys during their visits. This PI continued to conduct weekly meetings in the
outpatient setting to gather data on missed appointments, readmissions to the hospital, barriers to
distributing the SCP Questionnaire and EORTC-QLQ 25, and assessment of SCP Questionnaire
scores.
APRN participation in the outpatient setting was noted to be low. After interventions
were put in place for patients to fill out the questionnaires in in the waiting area, this created a
low role for APRNs to participate in this project. This incident was assessed in the beginning of
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March, and interventions were not put in place as the project only had approximately two weeks
prior to ending implementation.
Interprofessional Team Dynamics
The SCT project team consisted of a nurse manager, executive director, advanced
practice partner (APP), principal investigator, registered nurses (RNs), and advanced practice
registered nurses (APRNs). Prior to the implementation of the project, team assurance to
implementing quality care was established. Further qualities of the SCT team were responsible
for the success of this project. These additional qualities included effective communications
among team members, corresponding leadership roles with this principal investigator, and the
continuous commitment of all team members in the project’s goals.
Weekly meetings aided to achieve constant and effective communications among the
team members to attain optimal implementation each week. Tasks were completed due to the
presence of leadership members each week, team comradery, and continuous communication.
Professional leadership was noted in each member of the SCT team. Effective teamwork
was noted in this project because each member possessed leadership qualities that contributed to
the successful efforts of implementing this project. All nursing staff were capable and confident
in themselves, peers, and leadership members during the implementation phase. The SCT team
worked efficiently with this PI and the leadership members to monitor participants, identify
problems, and evaluate if new changes were effective using the PDSA cycles.
Lastly, this PI encouraged engagement in post-care of SCT patients. The nursing staff
and leadership members shared their concerns and opinions during each of the weekly meetings,
with decisions made being made as a team.
Process Flow Chart Variations
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The 30-day process flow for allogenic SCT patients involved substantial changes that
were monitored continually during the course of implementation by this PI. The section below
details the improved process flow of the allogenic SCT patients. See Appendix S for Final
Allogenic Stem Cell Transplant Flow Chart.
The original flowchart consisted of a room assigned to each allogenic stem cell transplant
patient on the bone marrow unit that arrived in the hospital admission area. The oncology
resident and this PI were notified via phone of the patient’s arrival to the bone marrow unit and
the admission process was completed by the admitting RN. This PI or nursing staff invited the
patients to participate in the project explaining the goals and aims. The patient voluntarily
signed the consent form within 72 hours and began their allogenic stem cell transplant process
the next hospitalized day in preparation to receive an allogenic stem transplant from their
perspective donor. As the implementation phase continued the process flowcharts improved
with each intervention used to improve the project.
The proposed process required modifications as the implementation phase continued over
the 10-week period. After the completion of the stem cell transplant a recovery period occurred
over seven to 27 days post-transplantation in patients without complications. Once the recovery
period was completed and blood counts where stable patients were prepared to discharge.
The final process chart consisted of the night prior to discharge, the nursing staff or this
PI met with the patient to implement the SCP Questionnaire and the discharge educational
material. The patient was discharged to local housing to begin their outpatient clinic visits
within one to two days post discharge. At the initial visit the SCP Questionnaire was
redistributed along with the EORTC-QLQ 25 by the oncology APRNs to assess knowledge
attainment of post-transplantation complications, aspects of their disease, and treatment.
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Evaluation
The evaluation of the Allogenic Stem Cell Transplant project was constant in monitoring
process, outcome, and balancing measures. January 13, 2021 through March 20, 2021, 11
patients were admitted to the bone marrow unit undergoing their allogenic stem cell
transplantation. A 100% of the participants (N=11) were enrolled over the course of the project.
The project enrolled five participants in January 2021 (45.4%), five participants in February
2021 (45.4%), and one in March 2021 (.09%). The mean age of the participants was 45 years of
age (N=11, SD=12.82) and had a small negative skew distribution with a mesokurtic curve with
a range of 27 to 67 years. The mean average score of the discharge SCP (pre-test)was 85.1%,
the mean average score of the outpatient SCP (post-test) was 100%. See Table 1 below for
descriptive data.
Variables included knowledge of post-transplant care, demographics, outpatient clinic
visit attendance, and health provider compliance. Inpatient setting healthcare compliance during
the implementation phase accounted for 100% (n=36) and the outpatient clinic compliance
accounted for 100% (n=4) . The total number of outpatient clinic visits for the 11 patients
during the 10-week project period accounted for 97% (n=297). Additionally, 54.5% (n=6) of
participants had a high school education or less, 27.7% (n=3) of participants had a two-year
degree, and .18% (n=2) of participants had a four-year degree or higher. Of the 11 consented
participants only one patient was African American with Caucasian ethnicity accounting for the
remaining 10 participants. Women participants accounted for 54.5% (n=6) and men participants
accounted for 45.4% (n=5) of the project. Lastly, 45.4% (n=5) of participants had an annual
income of less than $40,000, 45.4% (n=5) of participants had an annual income more than
$40,000 but less than $80,000, and .09% (n=1) of participants had an annual income more than
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$80,000. The income class was determined on a low-, middle-, and high-class system (Snider,
2020).
Table 1. Summary of Descriptive Data

Income Class

Education

low

middle

high

High School

2 year degree

4 year degree

Gender Class

5
6

low

middle

high

A paired sample t-test was conducted to determine if the average stem cell transplant
participant post-SCP questionnaire scores increased significantly from the pre-SCP questionnaire
scores. The average post-SCP questionnaire scores were significantly higher than the pre-SCP
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questionnaire scores, M=100, t(10) = 3.329, p=.007, compared to before (M=85.18). The
Shapiro Wilk’s Test of normality indicated that the normality assumption was violated
(W=0.763, p 0.003) the data was not normally distributed, and the sample size was also small
(N=11). A nonparametric test the Wilcoxon Signed Ranks Test was performed, due to the
violation of the Shapiro Wilk’s Test. The Wilcoxon Signed Ranks Test indicated that the postSCP questionnaire scores were statistically significantly higher than pre-SCP Questionnaire
scores Z=,-2.333 p<.020. The post-SCP Questionnaire knowledge mean demonstrated a
significant improvement over the pre-SCP questionnaire after receiving the SCP educational
material at discharge.
The findings from this project demonstrated a negative correlation between the
distribution of SCPs prior to discharge, the follow-up SCP Questionnaire during the outpatient
visits, and the absence of 30-day readmissions among the allogenic SCT patients. These findings
were consistent with this PI’s and the key stakeholder’s Needs Assessment and proposed project
objectives of reducing 30-day readmissions. Implementing a SCP at discharge improved patient
knowledge and understanding of preventative measures and common complications posttransplantation and proved to have a significant impact at this academic facility.
Missing Data
The collection of data for this stem cell project was difficult with a few reasons.
Readmission data for this stem cell project was not collected because readmissions did not occur
during the project’s time frame. Only eight patients of the 11 discharged patients had a 30-day
period to be evaluated.
There was also missing data on the phone calls received in the outpatient clinic, as only
two of the 11 patients had documentation in their charts about healthcare provider questions and
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phone calls returned by the APRNs. One of the patients required clarification about a posttransplantation medication and the other patient inquired about COVID-19 vaccination posttransplantation. This data was not identified until the end of implementation and interventions
were not put in place due to time constraints. Lastly, data was not collected for one week due to
the inclement weather and the closure of the clinic.
Process Measures
Process measure one within this project included the percentage of patients who received
survivorship care plans. Process measures two included the correct use and implementation of
SCPs by providers and the factors that prevented the correct use. Process measure three included
the correct use of the redistribution of the SCP Questionnaire and the EORTC-QLQ 25 in the
outpatient setting. Process measure four included measuring the percentage of patients who
completed the SCP Questionnaire and the EORTC-QLQ 25 at the initial visit and the SCP
Questionnaire once weekly for two weeks. Each weekly team meeting discussed measures to
address all insufficiencies and reported using descriptive statistics.
Survivorship Care Plan Capture Rate
The SCT patients capture rate was monitored weekly through the use of the EORTCQLQ 25 in the outpatient setting. There were two specific questions used from the EORTCQLQ 25 to help capture SCP distribution rates that directly asked the patient if written discharge
education material was received at discharge and if tips to managing your illness at home were
explained. Patients were not receiving post-transplantation educational material prior to this
project. The goal of this project was to initiate SCPs to 75% of discharged patients, but the goal
was exceeded and a 100% of patients received SCPs at discharge.
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Two patients discharged in January 2021, five patients in February 2021, and three in
March 2021, all with a capture rate of a 100%. See Table 1 for Survivorship Care Plan Capture
Rates.
Table 1. Survivorship Care Plan Capture Rates.

Survivorship Care Plan Capture Rates
6
5
4
3
2
1
0
#Survivorship Care Plans Dispersed

#Total Inpatient discharges
January

February

30 day readmission rate
March

Inpatient Healthcare Provider Capture Rates
The healthcare provider capture rate was assessed by a combination of information. The
information received from the retrospective chart review and the two specific questions used
from the EORTC-QLQ 25 helped to capture healthcare provider rates that directly asked the
patient if written discharge education material was received and tips to managing their illness at
home were explained. The information from the chart review revealed which nurse discharged
the patient for that day and that information was corresponded with the data from that particular
patient’s response on the EORTC-QLQ 25 questionnaire. The collection of data revealed that
each nurse discharged patients correctly and implemented the SCP at discharge which showed a
100% nurse compliance rate. See Table 2 for Inpatient Healthcare Provider Capture Rates.
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Table 2. Survivorship Care Plan Capture Rates.

Inpatient Healthcare Capture Rate
6
5
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3
2
1
0
January

February

#Survivorship Care Plans Dispersed

March
# Number of Inpatient Nurses

Outcome Measures
The outcomes of the SCT project demonstrated the overall success of increasing patient
knowledge and understanding of post-transplantation care. The outcomes evaluated include the
SCP Questionnaire pre- and post-survey scores.
Participant SCT Education. SCT participants were provided a pre-and posteducational questionnaire to determine if post-transplant knowledge improved. The EORTCQLQ 25 was used to assess if patients received a SCP, tips on managing their illness at home,
and possible side-effects of treatment. A 100% of participants reported receiving all written
information at discharge. The goal of this measure was to show a post-questionnaire mean
correlation score of 75%. The mean of the pre-educational questionnaire was 85.1 (N=11, SE=
4.425). The post-educational questionnaire demonstrated an increase of 14.9% in comparison
with a mean of 100% (n=11, SD=.00).
The projected goal of achieving a mean score of at least 75% for post-knowledge
educational questionnaire was successful. The educational measures illustrated that patients
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improved their overall knowledge of post-transplant care. These results can be correlated with
the routine use of a SCP provided at discharge as this tangible material provided a resource to
patients after discharging from the hospital. The information on tips for activities of daily living
and preventative measures aided in reinforce post-transplant self-care interventions provided by
this PI. See Table 3 for Summary of SCT Education.
Table 3. Summary of SCT Education
Variables

M

Range

SD

Age

45.6

40

12.83

Pre-Knowledge

85.18

38

14.68

Post-Knowledge

100

0

.000

Stem Cell Readmission Rates. An outcome measure was to reduce the readmission rate
by 50% by March 2021. Of the 11 participants, no patients were readmitted within the 30-day
period following their allogenic stem cell transplantation. A retrospective chart review from was
completed to demonstrate and signify a difference in samples. The chart review revealed there
were 22 allogenic transplants performed during October 2020 through December 2020. Of the
22 transplants performed eight patients were readmitted with complications of infections, GvHD,
and pneumonia with an admission rate of 36% (n=14).
A nonparametric test was conducted to emphasize the difference of samples where
readmissions was a dependent variable. The binomial test calculated whether the proportion
varied significantly from 36%, the pre-stem cell project readmission rate. The p-value calculated
was 0.039 with a level of significance p<0.05%. The results demonstrated the stem cell
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discharge program was significantly different. The project was effective in reducing 30-day
readmission rates by 36% to 0% (N=0). See Table 4. Stem Cell Readmission Rates.
Table 4. Stem Cell Readmission Rates.

Stem Cell Readmission Rates
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Unintended Consequences of Project
The implementation phase disclosed a few incidences that were unforeseen during the
pre-planning phase. The events were recognized but were unable to be revised to ensure the
corrections could be made to prior to completing the project.
In the outpatient clinic the APRN involvement was minimal and an unforeseen
constraint. APRNs did not have an active role in the outpatient setting and demonstrated a
decreased participation in leadership roles for this project. Interventions were not in place to
combat this consequence which would have proved beneficial if assessed earlier in the
implementation phase.
Data Maintenance and Security
Data was collected using an academic hospital system’s electronic medical record (EMR)
system. Data related to the project was stored on an Excel sheet on this PI’s password protected
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private computer with no one else to access it. See Appendix H for the project codebook. Data
collected includes:
•

Demographic information that included: gender, age, marital status, ethnicity,
educational background, and socioeconomic level

•

Distribution of SCP Questionnaire from the trained oncology RN

•

Distribution of SCP Questionnaire by trained APRN or oncology doctor

•

Attendance to follow-up visits

•

Missed appointments

•

Readmissions within 30 days after allogenic SCT

•

Complications that are related to 30-day readmissions

•

Interventions in the outpatient clinic to prevent deterioration after complications
are identified.
Discussion

Project Impact
The discharge project demonstrated substantial impacts for the participants in this project.
The participants learned imperative preventative measures and common complications to help
improve health outcomes post-transplantation. Understanding preventative care measures, tips
on activities of daily living precautions, signs and symptoms of common complications and the
usage of common medications post-transplantation were the primary focus of the education
provided. The improvement of post-transplant knowledge improved 14.3% over the course of
the project. The evidence-based education contained in the SCPs were useful to the overall
success of the discharge program.
Literature Comparison
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The stem cell discharge program replicated many outcomes from the literature in
reducing 30-day readmissions. Phillips et al. (2020) found that 68.8% of post-transplant patients
improved their post-care knowledge of cancer treatment and common complications after
receiving a survivorship care plan. Majhail et al. (2019) reported that 87% of survivors reported
SCPs to be useful with understanding side effects, related treatments, and post-care health
management. The implementation of this program and development project at this academic
facility reduced 30-day readmission to 0% during the 10-week implementation period. Krames
(2017), reported patients who received SCPs along with post follow-up care were 15% less likely
to be readmitted or visit the emergency department.
Economic and Cost Benefits.
Allogenic SCT hospital costs have grown 85% over the past two decades costing nearly
$1.3 billion annually to the healthcare system (Khrouf, 2017). Broder et al. (2017), found the
median total healthcare cost of allogenic SCTs were approximately $289, 283 for a hospital stay
of 35 days. Rauenzahn et al. (2015), concluded the median time for post-transplantation
readmission was 14 days and a median length of stay exhibited nine days. On average, 30-day
readmissions cost around $40,687 depending on the complications experienced by the allogenic
SCT patient and the severity of necessary treatment. (Cho et al., 2018).
Through the implementation of this DNP program and development project, a reduction
in healthcare costs and 30-day readmissions roughly saved this academic facility $18,000 per
allogenic SCT patient on 30-day readmission rates by improving after-hospital care instructions
(Kommers, 2019).
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Limitations
In spite of meticulous planning, there were notable limitations during this study: sample
size, sample profile, single facility, questionnaire usage and a short timeline are all restrictions
and elements that will be discussed as they may affect the final results.
Sample Size. The allotted timeline and slow admission of patients with acute myeloid
leukemia admitted to the project’s facility limited patient participation in this project. A larger
sample size would improve the power of the project.
Sample Profile. This project was limited to a specific population of allogenic stem cell
transplant patients. This project also excluded all patients below the age of 18, participants with
a life expectancy of less than 30 days, those who did not have a diagnosis of acute myeloid
leukemia, and those patients who previously received an allogenic SCT within the last year. The
exclusion of patients with previous experiences from multiple transplants was necessary as their
responses could create bias and taint the results of this project. All of these restrictions were
necessary components needed to qualify for an allogenic transplant on the bone marrow unit and
allowed for a homogenous sample for this project.
Single Facility. The use of one facility to identify if the evidence-based interventions of
this project improved post-care transplant patient knowledge is limiting. Some alterations may
be required to conduct this project into another similar facility to anticipate comparable
outcomes. Although there was statistical significance, each bone marrow unit has a variety of
transplant qualifications which may not demonstrate the results of multiple facilities admitting
allogenic patients.
Timeline. The SCT project’s implementation phase was limited to approximately 10
weeks which reduced the number of patients to participates in this project. The facility would

66
admit an average of 3-5 allogenic patients each month. An extended timeline would permit a
greater sample size that would increase the effect size of the project to improve statistical
significance.
Validity and Reliability of SCP Questionnaire. The SCP Questionnaire could generate
possible bias and limitations as this survey was strictly used for the purpose of this project and
independently designed by this PI. The validation and reliability of this survey could create
further bias as it was sought content and constructed by expert reviews from this PI’s project
committee members and a pilot test was not performed prior to implementation.
Limited Outpatient Clinic APRNs Involvement. The APRNs participation was very
limited which reduced the intended involvement with patients in the outpatient setting. This
limitation could create decreased opportunities for leadership involvement in the outpatient
setting. This limitation could lessen beneficial educational opportunities in the outpatient setting
to improve overall patient health outcomes.
Factors Limiting Transferability
The stem cell project was designed specifically for an academic facility where this PI
performed this project. This academic facility assembled its own standards, principles, and
structural framework. The care provided by each stem cell bone marrow unit are required to
meet state and federal standards that command the level of care provided and varies among each
program. Because of the variations among each stem cell bone marrow program, changes may
be required to transfer and adapt in a similar stem cell program into another healthcare facility.
Threats to Internal Validity
Confounding Variables. This stem cell bone marrow unit only performs transplants to
acute myeloid leukemia patients. This specific cancer population only account for 16% of
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patients eligible for allogenic stem cell transplants (Mayo Clinic, 2020). Not knowing how other
cancers may respond to this same educational material in similar facilities presents potential
threats to the internal validity of this project.
Efforts to Decrease Limitations
Limitations recognized during the implementation phase such as timeline, staff shortage,
and sample size are difficult variables to control and affected the project’s outcome
measurements. The limitations such as sample profile and incentive measures were implemented
to reduce interference with outcomes. The sample profile exclusions were implemented as it
eliminated the stem cell patients that received previous transplants within the last year. This
population would potentially alter the outcomes due to the pre-existing complications from
previous transfusions and prior experiences and expectations from previous transplantation.
Inclusions should be considered in projects with a larger sample size. This PI offered two gift
cards as incentives to help combat low nurse participation at the beginning of the project. Due to
staff shortage in the inpatient setting and minimum financial resources needed for
implementation, staff members volunteered with the PI being the most consistent educator and
data collector during this project.
Recommendations
As the stem cell transplant project changes into the new discharge policy, there are
recommendations that will increase the efficiency in providing education to patients with cancer.
Recommendations for future endeavors include more active interventions from the
APRNs. APRNs could serve as leaders and resources to collaborate with other interprofessional
team members and improve the healthcare outcomes for this patient population. Future studies
should ensure that APRNs have an active role and demonstrate a present leadership role in the
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outpatient clinic. Evaluation of telephone calls placed and received by patients and APRNs
should be monitored closely to determine information that could be gathered to further support
efforts to increase the efficacy of future projects.
It is recommended that the nursing management provide an opportunity for nursing staff
members to become leaders in this new program. The leaders of this discharge program will
continue to implement changes as necessary and add resources that improve the educational
materials. The leaders could provide online modules for continual education while using the
same program guidelines to guarantee methods are carried out effectively.
As time progress with the use of this project, a Telephone Initiated Guided Response
(TIGR) video could be created for patients to watch in their rooms on the television prior to
discharge. The paper copies could be made electronic and emailed to patients to provide readily
available information at their fingertips. APRNs and nursing staff are encouraged to add
information to the discharge education material to increase the usefulness to patients and their
families after discharging.
Sustainability
This project demonstrated a strong commitment to reduce 30-day readmission rates and
deliver the greatest care to the allogenic stem cell transplant patients at any hospital. The stem
cell project was successful in educating patients about preventative measures, common
complications, and improving post-transplantation care knowledge. Administration support is an
important element to the sustainability of any project. The benefits and the progressive
outcomes of this mainstay program within the academic facility have been accepted by senior
stakeholders and staff members. The administration at this academic facility were vested,
supportive, and passionate towards this project and its positive impact decreasing 30-day
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readmissions in the oncology department. The bone marrow unit will continue to make the
discharge protocol the standard of care for allogenic SCT patients. The PowerPoint presentation
was made available in the conference room located on the unit to aid in continued staff
education.
This PI released all duties to the nursing leadership in preparation for the longevity of this
project on the bone marrow unit. All resources from this project were distributed to each of the
staff members and leadership members to continue monitoring outcome and process
measurements. Over time, practices may change as different guidelines and procedures improve,
nonetheless the fundamental principles of this stem cell project will remain in place.
Healthcare Quality Impact.
Allogenic SCTs have a massive impact on the lives of transplant patients and their
families (Bell et al., 2017). Evidence from the review of literature indicated that SCPs in the
clinical setting provided a safe practice that was associated with increased patient knowledge of
preventative measures and improved health outcomes (Seto et al., 2018). SCPs assigned
responsibility for managing ongoing post-transplant care and provided the necessary tools to
support patient engagement in conversations about prevention, follow-up care, and other
concerns when meeting with their oncology healthcare providers (Selove et al., 2016). The stem
cell transplant program reduced 30-day readmission rates among allogenic stem cell transplant
patients while improving patient knowledge and understanding of post-transplantation care. All
interventions provided in this project were evidence-based research efforts that provided overall
quality care and resources to patients suffering with acute myeloid leukemia. Through the
utilization of the SCP educational material and continuous monitoring, patients were able to
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discharge home safely with preventative measures at their fingertips to utilize after
transplantation.
This project may also help with reducing hospital costs to patients and Medicare by
improving communication and care coordination in discharge plans and reduce avoidable
readmissions (Centers for Medicare & Medicaid Services, 2020).
Policy Implications.
There were no policies or protocols for the discharge process on the bone marrow unit.
The implementation of this DNP project assisted with developing a discharge policy that created
awareness for improving patient education during the discharge process in this healthcare
system. This project demonstrated the ability to monitor and evaluate improvements in patient’s
knowledge of post-transplant care. Implementing policy changes with this project should be
considered in this academic facility as patients demonstrated increased knowledge and improved
health outcomes as there were no 30-day readmissions noted.
Dissemination
The results of this project will be disseminated virtually to the DNP committee at the
University of Arkansas, Eleanor Mann School of Nursing and the academic facility where this
project was implemented using a PowerPoint presentation. The results of this project will be
shared with the community oncology members interested in providing evidence-based care to the
leukemic population.
Project outcomes will be shared with the local academic facility oncologists, nurse
practitioners, and registered nursing staff to demonstrate the effectiveness and benefits of using
educational information at discharge. Through the use of the evidence-based information
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provided these healthcare professionals can incorporate key teaching points into their everyday
practice.
Professional Reporting.
Dissemination via professional reporting will emphasis the importance of this project and
highlight the positive outcomes of increased knowledge of post-transplantation and decreased
30-day readmission rates. Project results will be distributed to the Journal of Oncology, the
American Journal of Clinical Oncology, and the Journal of Cancer Research & Clinical
Oncology. Future endeavors are to provide a PowerPoint presentation at the local level during
the St. Vincent’s Infirmary Oncology & Chemotherapy trainings for annual certification hours.
Lastly, the dissemination of these results can be presented in the near future to the Arkansas
Clinical Oncology Association and Hematology Society and the Arkansas Cancer Summit all
held annually to showcase recent progress in meeting the goals and objectives of the state’s
comprehensive cancer plan.
Conclusion
This DNP project illustrated the usefulness of a routine discharge program implementing
SCPs along with a follow-up questionnaire among allogenic SCT patients. Evidence supported
the use of routine SCP and follow-up measures to decrease 30-day readmission rates. The
implementation of SCPs provided allogenic SCT patients with post-transplantation knowledge of
preventative measures and post-transplant complications. Over the 10-week period, this project
demonstrated patient education on post-transplantation care was a milestone for reducing 30-day
readmission rates among stem cell transplant patients. Providing evidence-based educational
material has shown to significantly increase patient knowledge of preventative measures.
Although further research is needed to determine if this program would continue to decrease
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readmissions, this project demonstrated that both nursing interventions and patient education
could significantly reduce 30-day readmission rates.
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Appendix A: Global Aims Assignment

The Effects of a Survivorship Care Plan on Hospital Readmission
Rates in Allogenic Stem-Cell Transplant Patients
Global Aim Statement
Write a Theme for Improvement:

Create an aim statement that will help keep your focus clear and your work productive:
We aim to decrease readmission rates of allogenic stem-cell patients post transplantation
(Name the process)
In: UAMS E7 Bone Marrow Transplant Unit
(Clinical location in which process is embedded)
The process begins with:

implementing survivorship care plans during the discharge process
(Name where the process begins)

The process ends with: with decreasing readmission rates
(Name the ending point of the process)
By working on the process, we expect: decrease readmission rates
(List benefits)

it is a gap in care for post-transplantation complications that
necessitate readmission within four months post transplantation among allogenic patients
It is important to work on this now because:

(List imperatives)

Create Flowchart
Specific Aim Statement
We will:
The:

improve
quality of

increase

decrease

number/amount of

readmission rates among allogenic patients
(process)

By: 25 percent
(percentage)
OR
From:
(baseline state/number/amount/percentage)
To/By: implementing a survivorship care plan during the discharge process and assess information perceived by patient
utilizing the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire 25
(EORTCQL-25).

ING
By: 05.01.2021
(08.02.2020)
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Appendix B: Original Process Flowchart
Patient accepted
to be an
allogenic stem
cell transplant
(SCT) in
outpatient clinic

Patient
educated about
SCT and
consented

tPatient
agrees to
SCT

Specific
education
provided
about SCT

Patient is prepared for
inpatient hospital stay
for SCT a minimum of
30 days

Key Guide to Process Flowchart

Patient has to “nadir”
down and recover count
to be discharged

DDay “0”
patient receives
SCT

CVL placed by IR & 7
days of conditioning
chemotherapy is
ordered

Patient arrives
for inpatient
status nurse is
assigned

pSCT is
scheduled for
the future

Counts have recovered
patient experiencing no
complications ready for
discharge

tPatient agrees
and is ready for
discharge and has
local housing set
up

Specific education
provided about
post-transplant
care via
survivorship care
plan

Patient discharged
home with care plan
and follow-up
schedule with
outpatient oncologist
in 2-3 days
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Symbol

Name

Function

Circle

Represents a start and
endpoint

Rectangle

Represents input/output

Square

Represents a process

Cloud

Represents educational
process

Arrow

Represent action that has
taken place

Line

Represents a connection
between two related points
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patients

Retrosp
ective
study

N=15

Electronic health records

A structured and intense followup process in the first 60 days
post-transplant may be the most
effective for reducing and
identifying preventable
readmissions
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0
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No theory
applicable

Treatment
summaries
and followup care

SCPs, selfcare
efficacy
and health
care
utilization
among
allogenic
transplant
patients

System
atic
review

N=20 patients

Data collected between
January 2011 and June
2017 via surveys

Written treatment summary and
follow-up care plans enhances
survivor self-efficacy for
managing cancer

I

2 USA
0
1
6

No theory
applicable

SCPs

Cancer
survivors
and health
care
providers

System
atic
review
and
metanal
ysis

N=29

Randomized study

Oncology providers supported
the use of survivorship care
plans, but reported significant
barriers for provision

I

2 USA
0
1
3

No theory
applicable

Readmission
s and high
risk factors
and
preventative
measures

Allogenic
SCT

RCT

N=235

Data collected by trained
staff using electronic
medial charts

High risk patients readmissions
are common. Enhanced
education and follow-up through
phone calls may decrease
readmission rates.
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No theory
applicable

SCPs

Survivorshi
p and
clinical
assessment

Retrosp
ective
review

N=29

Electronic health records

Survivorship care plans will help
to improve the design for future
SCPs for use by stem-cell
survivors

II

2 USA
0
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No theory
applicable

Risk-factors
for 100-day
readmissions

Allogenic
stem cell
transplants

Cohort
study

N=125

Data was obtained via
survivor interviews

This study showed that risk
factors within 100 days of
discharge did not affect nonCaucasian race
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Appendix D: Theoretical Framework
Kurt Lewin’s Change Theory
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Appendix E: Conceptual Model

Allogenic Stem-Cell Transplant
Patients are experiencing posttransplant complications necessitating
hospital readmission within 2 months
necessitating hospital readmission
within 4 month

Infection

Increase healthcare
cost

GvHD
Prolong
Hospital
Utilization

Ineffective
discharge
preparations

Lewin’s Change Theory

Contributing Factors
Medical
Complications

Lack of
Materials
Lack of
Education
Unfreezing

Improve Patient
Knowledge

Improve Care
Management

Decrease
readmission rates

Benefits

Survivorship
Care Plan

Identification of problem
Gather data for problem
Determine staff/patient
readiness for change

Goal

Implement Survivorship Care
Plans prior to discharge to
decease readmission rates

Changing

BY

DNP Project
Implementatio
n

Refreezing

Develop survivorship
care plan
Support change
through positive
reinforcement
Encourage feedback to
improve care plan

Evaluate integration of
change
Evaluate sustainability
and effectiveness
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Appendix F: Proposed Gantt Chart
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Appendix G: Statement of Mutual Agreement for DNP Guidance
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Appendix H: Data Collection Sheets

SCP Questionnaire
Survey Link:
https://uark.qualtrics.com/jfe/form/SV_0f7m7K5mdVkOIeh
Variable
Variable
Variable Label
Value and Label
Name
Type
We are interested in the information you have
received from the survivorship care plan
reviewed with you and your family prior to
discharging home. This packet discussed
information on preventative measures and
Q1
Text
common complications. Please answer ALL
questions yourself by circling the choice(s)
that best answers the question. The
information that you provide will remain
strictly confidential.
1. Notify your doctor immediately or go to
the nearest emergency department
If you had a temperature of 100.4 or greater,
Q2
Numeric
2. Take Tylenol and recheck 1 hour later
would you?
3. Use cool compresses to reduce fever
4. Do nothing because this is normal
1. Temperature of 100.4 or greater
2. Shaking chills with or without fever
Q3
Which best describes symptoms of infection? Numeric
3. Redness, swelling, or drainage at your
central line site
4. All of the above
1. Handwashing 20-30 seconds regularly
Q4
Which best describes infection prevention?
Numeric
before eating, after toileting, coughing,
sneezing, and touching pets
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Variable
Variable Label
Name

Variable
Type

Q5

Which complications are the most common
after transplantation?

Numeric

Q6

Which of these preventative measures are
important?

Numeric

Q7

Which best describes a scenario that should
be reported to your oncologist?

Numeric

Q8

Which best describes common medications
that you will be prescribed after your
transplantation?

Numeric

Value and Label
2. Being in contact with people who are
sick and contagious
3. Only bathing or showering once every
7 days with antibacterial soap
4. There is no such thing as infection
prevention
1. Infection, Cytomegalovirus, and Graft
versus Host Disease
2. Hepatitis A, Hepatitis C
3. Colon cancer and rectal bleeding
4. Hyperlipidemia and Hypertension
1. Drinking alcohol heavily with more than
2 drinks a day
2. Staying physically active (2.5 hours each
week with moderate exercise)
3. Eating an unhealthy diet with plenty of
fast food.
4. Sitting on the couch for 8-10 hours a
day
1. You should never report any symptoms
2. Exposure to chickenpox or shingles
3. A headache that resolved within 2
hours
4. An increased appetite
1. Antivirals
2. Immunosuppressants
3. Antifungals
4. All of the above
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Variable
Variable Label
Name

Variable
Type

Q9

If your central catheter site becomes painful,
swollen, or red you should?

Numeric

Q10

This last set of questions gives us information
about the type of sample we collected. Thank
you for your assistance.

Text

Q11

Select the gender identity that best represents
Numeric
you

Q12

Select the highest level of education you have
completed.

Numeric

Q13

Select the race or ethnicity that best represent
you

Numeric

Q14

Please enter your age

Text

Q15

What is your household income category?

Numeric

Value and Label
1. Just remain calm the pain will go away
2. Try to take the dressing off to relieve
the pain
3. Call the clinic or your oncologist
immediately
4. Take Tylenol this is a normal reaction

1.
2.
3.
1.
2.
3.
4.
5.
6.
7.
1.
2.
3.
4.
5.
6.

Male
Female
Other
Less than high school
High school graduate
Some college
2 year degree
4 year degree
Masters’ degree
Doctorate or professional degree
White
Black or African American
American Indian or Alaska Native
Asian
Hispanic
Other

1. $0 - $39,999
2. $40,000 - $79,999
3. $80,000 - $119,999
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Variable
Variable Label
Name

Are you now married, widowed, divorced,
separated, or never married?

Variable
Type

Numeric

Value and Label
4.
1.
2.
3.
4.
5.

$120,000 or more
Married
Widowed
Divorced
Separated
Never married
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Appendix H: Data Collection Sheets
Codebook
EORTC-QLQ-INFO25 Questionnaire
Survey Link:
https://uark.qualtrics.com/jfe/form/SV_cBUQuvptiTjYYDz
Variable
Variable
Variable Label
Value and Label
Name
Type
We are interested in the
information you have received
about aspects of your disease
and its treatment, in order to
improve your health care. Please
Q1
answer ALL questions yourself
Text
by circling the number that best
applies to you. There are no
right or wrong answers. The
information that you provide will
remain strictly confidential
1. Not at all
The purpose of any medical tests
2. A little
Q2_1
Numeric
you had undergone?
3. Quite a bit
4. Very much
1. Not at all
The results of the medical tests
2. A little
Q2_2
Numeric
you received?
3. Quite a bit
4. Very much
1. Not at all
The medical treatment
2. A little
Q2_3
(chemotherapy, radiotherapy, or Numeric
3. Quite a bit
surgery)?
4. Very much
1. Not at all
The possible side-effects of your
2. A little
Q2_4
Numeric
treatment?
3. Quite a bit
4. Very much
1. Not at all
Tips of managing your illness at
2. A little
Q2_5
Numeric
homes?
3. Quite a bit
4. Very much
Did you receive written
1. Yes
Q3
Numeric
information at discharge?
2. No
Do you wish to receive more
1. Yes
Q4
Numeric
information?
2. No
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Variable
Variable Label
Name
Please specify which topics you
Q5
wish to receive more information
Do you wish to receive less
Q6
information?
Please specify which topics you
Q7
wish to receive more information

Variable
Type

Value and Label

Text
Numeric

1. Yes
2. No

Text

Q8

Overall has the information you
received been helpful?

Numeric

Q10

Select the gender identity that
best represents you

Numeric

1.
2.
3.
4.
1.
2.
3.
1.
2.

Q11

Select the highest level of
education you have completed.

Numeric

3.
4.
5.
6.
7.
1.
2.

Q12

Select the race or ethnicity that
best represent you

Numeric

3.
4.
5.
6.

Q13

Q14

Please enter your age

What is your household income
category?

Not at all
A little
Quite a bit
Very much
Male
Female
Other
Less than high
school
High school
graduate
Some college
2 year degree
4 year degree
Masters’ degree
Doctorate or
professional
degree
White
Black or African
American
American Indian
or Alaska Native
Asian
Hispanic
Other

Text

Numeric

1. $0 - $39,999
2. $40,000 $79,999
3. $80,000 $119,999
4. $120,000 or
more
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Variable
Variable Label
Name
Q15

Are you now married, widowed,
divorced, separated, or never
married?

Variable
Type
Numeric

Value and Label
1.
2.
3.
4.
5.

Married
Widowed
Divorced
Separated
Never married
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Appendix I: Patient Education Materials

Blood and Marrow Transplant Survivor Care Plan
Congratulations on your allogenic stem cell transplant. Thank you for joining the
Survivorship Care Plan for Allogenic Survivors study. This packet contains the
following materials:
• Your personalized care plan
• Preventative Measures for Infection
• Common Complications post-transplantation
• Common Medications post-transplantation
• Activities of Daily Living Precautions
This Survivorship Care Plan includes a summary of information relevant to you and is
important to share with your oncologist and other medical care providers. Your
doctor may recommend or order other tests or evaluations on a different schedule
based on your specific situation. Follow his or her recommendations carefully.
Transplant follow-up care is important to protecting your health, even many years
after transplant. Your care plan is organized in sections to better assist you with
understanding each component.
For this study, treatments before your transplant are not included in this survivorship
care plan, please contact your oncologist for your questions about treatment before
transplant.
We will use your feedback to improve Survivorship Care Plans for the future.
Sincerely,

Chantaney Williams, University of Arkansas Mann DNP Student
Principal Investigator
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Blood and Marrow Transplant Survivor Treatment Summary
For:
Date Your Treatment Summary was Created:
If you need to go to urgent care or the emergency room, it is helpful
to take the care plan with you.
Your Medical Information
Date of Birth:
Sex:
Diagnosis:
Date of Diagnosis:
Your Transplant Information
Transplant center name: UAMS E7 & UAMS Winthrop R. Rockefeller Cancer
Institute
Address: 4018 W Capitol Ave. Little Rock, AR 72205
Phone Number: (501) 296-1200
Transplant MD:
Date of Transplant:
Age at Transplant:
Transplant Type:
Cell source type: peripheral stem cell
Chemotherapy drugs:

Total Body Irradiation (TBI): (dose and dose unit:)
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Recommendations for your Preventative Care
IMMUNE SYSTEM
o Wear masks out in public places and large crowds
o Avoid people who are sick or have been recently sick
o Wash hands frequently 20-30 seconds with antibacterial soap or use alcoholbased hand sanitizer
o Vaccines to prevent infections (once cleared by oncologist)
EYES
o Wear sunglasses every time you go outside.
o Vision screening once a year by your eye doctor to check how well you can
see
MOUTH
o Dental exam and teeth cleaning by a dentist at least once a year.
o Use a soft bristle toothbrush
o Brush your teeth regularly and maintain a moist mouth using mild solutions
(biotene)
o
LUNGS
o Don’t smoke or use chewing tobacco. Stay away from second-hand smoke
HEART AND BLOOD VESSELS
o Blood pressure should be checked every time you visit the clinic
o Blood tests to check your cholesterol level at least once a year. This includes
triglycerides, LDL, and HDL
LIVER
o Liver function blood test at least once a year
KIDNEYS AND BLADDER
o Blood pressure should be checked every time you visit the clinic
o Kidney test at least once a year including testing on protein levels in your
urine.
BONES
o Bone density scan test once a year
SKIN
o Do a self-exam of your skin every month to check for any changes (rash,
unusual growth, or patches)
o Use sunscreen with SPF 15 or higher every time you go outside. Reapply at
least every 2 hours, or more often if you’re sweating or in and out of the
water
o Avoid direct sunlight. Wear a broad-brimmed hat or use a large umbrella to
protect your skin.
o Use an electric razor when shaving
NERVOUS SYSTEM
o Clinical exam by your doctor at least once a year for changes or problems
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ENDOCRINE ORGANS
o Blood test to check how well your thyroid is working
o Blood test to assess your sex hormones
o Fasting glucose (sugar) test to check for diabetes
GENITALS AND SEXUAL HEALTH
o Gynecology exam at least once a year for women
o Discuss with your doctor if you are experiencing sexual side effects such as
vaginal dryness, pain with sex, or difficulty having an erection
FERTILITY AND FAMILY PLANNING
o If you want to have children in the future, ask your doctor to refer you to a
fertility doctor
EMOTIONAL HEALTH
o Going through a transplant is a very emotional experience. Your feelings
and needs will change a lot, maybe even every day. It’s important that you
talk openly and regularly with your oncologist, family, and friends.
DIET AND NUTRITION
o Eat a healthy diet
o Keep yourself well hydrated
o Avoid foods with lots of processed (fake) sugar or saturated (bad) fat
GENERAL HEALTH
o Use alcohol in moderation (less than 2 drinks a day)
o Stay physically active (2.5 hours each week of moderate exercise)
o Avoid people that are sick or contagious
Central Catheter Line Care
Check your site daily for:
o Redness
o Tenderness
o Leakage
o Swelling
o Bleeding
Call the clinic or your oncologist right away if:
o You have redness, swelling, or drainage around the area where the catheter
exists your body
o Your needless connector falls off
o You have a temperature of 100.4 or greater
o You have a break or leak in your catheter
o You have an unexplained problem with your catheter

Adapted from Memorial Sloan Kettering Cancer Center
https://www.mskcc.org/cancer-care/patient-education/leaving-hospital-after-yourallogeneic-transplant
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Summary of Common Complications
Infection

Cytomegalovirus

Graft versus Host Disease

S/S:
•
•
•
•
•
•
S/S:
•
•
•
•
S/S:
•
•
•
•
•

Interstitial Pneumonitis

Hepatic Sinusoidal Obstruction
Syndrome

Bleeding

S/S:
•
•
•
•
•
•
•
S/S:
•
•
•
•
•
S/S
•
•

Fever (100.4)
Chills & Sweat
Shortness of breath
Burning or pain with urination
Change in cough or a new cough
Sore throat or new mouth sore

Fever (100.4)
Sore Throat
Fatigue
Swollen glands
Rash, raised, or discolored area
Yellow discoloration
Nausea, vomiting, diarrhea, or
abdominal pain or abdominal
swelling
Dry eyes or visual changes
Dry mouth, white patches inside
the mouth, pain, or sensitivity
Shortness of breath
Dry, hacking cough without
phlegm
Extreme tiredness and weakness
Decrease or no appetite
Unexplained weight loss
Mild pain in chest
Labored breathing
Abdominal pain
Fluid retention
Jaundice
Ascites
Enlarge liver
Tiny, purplish-red spots on your
skin
Bruising
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•
Mucositis

S/S:
•
•
•
•
•
•

Nausea & Vomiting

Diarrhea

Sexual dysfunction & Infertility

Secondary New Cancers

S/S:
•
•
•
•
•
•
S/S:
•
•
•
•
•
•
S/S:
•
•
•
•
•
S/S:
•
•
•
•
•

Bleeding from rectal area, gum, or
nose
Red, shiny or swollen mouth and
gums
Blood in the mouth
Sores in the mouth, gums, or
tongue
Soreness or pain in the mouth or
throat
Difficulty swallowing
Feeling of dryness, mild burning,
or pain
Abdominal pain
Lightheadedness
Vertigo
Rapid pulse
Excessive sweating
Dry mouth
Frequent loose, watery stools
Abdominal cramps
Abdominal pain
Fever
Lightheadedness or dizziness
Dehydration
Vaginal dryness
Irregular periods or no periods
Erectile dysfunction
Decreased libido
Painful intercourse
Esophageal
Gastric
Lung
Breast
Oral

Adapted from UC Davis Medical Center https://secure.ucdmc.ucdavis.edu/cancer/Specialties/stemcell-transplant/pdf/SCTdischarge.pdf
Adapted from American Cancer Society https://www.cancer.org/treatment/treatments-and-sideeffects/treatment-types/stem-cell-transplant/transplant-side-effects.html
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Common Medications Used After Transplant
This is a list of common medications used after a transplant to treat infections that can
occur when the immune system and white blood cell counts are suppressed. **Your
oncologist may prescribe other medications depending on your health status.
Name
SMX/TMP
(Bactrim, Septra)

Type of Drug
Antibacterial

Why Used
Used to prevent
bacterial
pneumonias

Fluconazole
(Diflucan)

Antifungal

Posaconazole
(Noxafil)

Antifungal

Voriconazole
(Vfend)

Antifungal

Used to treat
and prevent
fungal
infections
Used to treat
and prevent
fungal
infections
Used to treat
and prevent
fungal
infections

Valacyclovir
(Valtrex)

Antiviral

Acyclovir

Antiviral

Valganciclovir

Antiviral

Ganciclovir

Antiviral

Used to treat
and present
herpes (HSV)
viral infections
Used to treat
and present
herpes (HSV)
viral infections
Used to treat
cytomegaloviru
s (CMV) and
other viral
infections
Used to treat
cytomegaloviru
s (CMV) and
other viral
infections

Side effects
Rash,
electrolyte
disturbances,
decrease in
platelets
Abdominal
pain, liver
abnormalitie
s
Liver
Function
abnormalitie
s
Liver
Function
abnormalitie
s and visual
changes
Nausea,
kidney
effects
Nausea,
kidney
effects
Decreases
white blood
count and
nausea
Decreases
white blood
count and
nausea
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Tacrolimus
(Prograf)

Immunosuppressive

Used to prevent
graft vs host
disease (GVHD)

Cyclosporine
(Neoral or
Gengraf)

Immunosuppressive

Used to prevent
graft vs host
disease (GVHD)

Sirolimus
(Rapamue)

Immunosuppressive

Mycophenolate
mofetil
(Cellcept)

Immunosuppressive

Used to prevent
graft vs host
disease (GVHD)
Used to prevent
graft vs host
disease (GVHD)

Prednisone
(Deltasone)

Antiinflammatory/Immunosuppressiv
e

Ondansetron
(Zofran)

Anti-nausea

Prochlorperazin
e (Compazine)

Anti-nausea

Lorazepam
(Ativan)

Anti-nausea

Used to prevent
graft vs host
disease (GVHD)
and other
inflammatory
conditions
Used to treat
and prevent
nausea
Used to treat
and prevent
nausea
Used to treat
and prevent
nausea

Increased
blood
pressure,
tremors,
kidney
effects
Increased
blood
pressure,
tremors,
kidney
effects
Liver effects,
increased
triglycerides
Decreased
blood
counts,
nausea
Insomnia,
increased
blood sugar,
bone effects
Constipation
and
headache
Drowsiness
Drowsiness
and dizziness

References
The Centers for Diseases Prevention and Control (2000).
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm
UNC Cancer Care. (2012). https://unclineberger.org/files/2018/10/allogenic.pdf
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Activities of Daily Living Education
Discharging Home from the Hospital: Transplant team members will provide you
with the information about your post-transplant care. It is important to ask questions
and take notes. Some common guidelines regarding discharge planning and home
care are listed below:
•

•

•
•

•

General Protection: Wear a mask at all times while in public and visiting the
hospital property, especially in waiting rooms. Wash hands for 20-30 seconds
or use hand sanitizer regularly before eating, after toileting, coughing,
sneezing, and touching pets
A clean home: Your home should be thoroughly cleaned at least a few days
before you are discharged due to your risk for infection. Special attention
should be given to the floors, carpets, bathtubs, sinks and toilets. Have the
filter on your ventilation system changed to decrease dust and dirt. You are
not allowed to clean: Let your family and friends clean for you and please
stay out of the room they are cleaning. Cleaning should be done on a regular
basis.
Do not share: Use your own utensils, towels and toothbrush. Clean bath
towels and linens regularly in HOT water.
Plants and Flowers: Limit the number of plants and flowers in your house.
DO NOT take care of them. Allow your caregiver to water and re-pot them.
You should avoid caring for plants and gardening for six months and during
periods of substantial immunosuppression. Once you are able to garden, you
must use garden gloves and we recommend wearing a mask.
Pets: You can keep your pets in your home, and you CAN pet them.
Remember to wash your hands afterwards. DO NOT clean litter boxes, bird
cages, fishbowls, etc. DO NOT handle animal excretions for at least 1-year
post-transplant

Infection Prevention: At any time when a stem cell transplant patient develops a
temperature 100.4 or greater call your oncologist or go to the nearest emergency
department. DO NOT take any Aspirin, Acetaminophen (Tylenol), or Nonsteroidal
Anti-Inflammatory Drugs (NSAIDs) without consulting with your oncologist.
Infection & Neutropenia: Infection is the most common side effect of
transplantation. This is due to the destruction of white blood cells (that help
fight infection) by chemotherapy. Infections can come from the environment,
but the most common source of infection is bacteria originating from the
patient’s own body. It is recommended that allogeneic transplant patients
follow the guidelines listed below to prevent infection:
•
•

bathe or shower daily with antibacterial soap
good oral hygiene with mouth care to be done as prescribed
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•
•
•
•

cleanse rectal area after each bowel movement
avoid contact with people who have colds, flu, chicken pox, or any other
contagious disease
handwashing 20-30 seconds regularly before eating, after toileting,
coughing, sneezing, and touching pets
take antibiotics/antivirals/antifungals as prescribed

Calling the Transplant Team
If you do get an infection, your doctor should be notified immediately. The following
is a list of signs and symptoms that should be reported:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

A temperature greater than 100.4 degrees F.
A persistent cough.
Shaking chills with or without fever.
Persistent nausea and vomiting.
Persistent pain.
Diarrhea, constipation or pain with bowel movements.
Shortness of breath.
Excessive fatigues, irritability, or lethargy.
Chills that occur after your central line is flushed.
Redness, swelling, drainage, or tenderness at your catheter site.
Pain, burning, or increased frequency with urination.
Sores in the mouth or throat.
Any sore or wound that does not heal.
Swelling in any area after injury.
Unusual vaginal discharge or itching.
Development of a rash on your skin.
Presence of blood when vomiting.
Blood in your urine or stools (red or black).
Persistent nausea, vomiting, constipation, or diarrhea.
Exposure to chicken pox.
Sudden bruises or hives.
Headache that persists or any severe headache.
Blurry vision.
Persistent dizziness.

Call 911 in an emergency situation.
References: The Centers for Diseases Prevention and Control (2000).
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm
Adapted from UC San Diego Health.
https://health.ucsd.edu/specialties/cancer/programs/hematologic/BMT/Documents/
PH1156.pdf
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Appendix J: Needs Assessment Questionnaire with Analysis
Needs Assessment Questionnaire
The purpose of this questionnaire is to gather information regarding the care of patients
who undergo allogenic stem cell transplantation. This information will be used to help
improve patient health outcomes post-transplant once discharged from the hospital. All of
the information collected from this survey will be kept confidential. This questionnaire should
take approximately 15-20 minutes to complete.
Role: Administration (1), MD (1), CSM (1), APRN (2), RN (4)
Employment Status: Full time (9)
1. What causes patients to be re-admitted or seen acutely ill following procedures?
• Uncontrolled Nausea & Vomiting
• Diarrhea
• Failure to thrive
2. What are the most common complications experienced by patients readmitted after
allogenic stem cell transplant?
• Infection
• C-Diff
• Elevated LFTs
• Graft vs Host Disease
3. What changes can be made to improve patient health outcomes?
• Frequent Readmissions
• Inadequate Self Care knowledge
• Workload demand for RNs
• Failure to recognize high-risk patients
• Ineffective discharge planning
• Lack of resources and education
4. What aspects of the discharge process need to be improved?
• Preventative Care Measures
• Personalized Education to patient and family
• When to seek medical care
• Transplant knowledge
5. Are allogenic patients are given all the tools needed to be successful at home
following discharge? If no, explain why. (Examples: proper education related to
medications, health, diet, etc.).
• No reported by 75% of nurses because there is no standardized discharge process
that provides the necessary materials that patient’s need
• Yes
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6. Are staff members prepared to make changes in terms of a standardized discharge
process?
• Yes reported by 100% staff and stakeholders
• No
7. Do you feel that management will support ideas to improve the discharge process
to reduce readmissions?
• Yes (100%)
• No (0%)
8. Are you willing to help implement a change using a standardized discharge
process?
• Yes (100%)
• No (0%)
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Appendix J: Survivorship Care Plan Questionnaire
We are interested in the information you have received from the survivorship care
plan reviewed with you and your family prior to discharging home. This packet
discussed information on preventative measures and common complications. Please
answer ALL questions yourself by circling the choice(s) that best answers the
question. The information that you provide will remain strictly confidential.
Demographic information is needed to help with future research.
1. If you had a temperature of 100.4 or greater, would you?
o Notify your doctor immediately or go to the nearest emergency
department
o Take Tylenol and recheck 1 hour later
o Use cool compresses to reduce fever
o Do nothing because this is normal
2. Which best describes symptoms of infection?
o Temperature of 100.4 or greater
o Shaking chills with or without fever
o Redness, swelling, or drainage at your central line site
o All of the above
3. Which best describes infection prevention?
o Handwashing 20-30 seconds regularly before eating, after toileting,
coughing, sneezing, and touching pets
o Being in contact with people who are sick and contagious
o Only bathing or showering once every 7 days with antibacterial soap
o There is no such thing as infection prevention
4. Which complications are the most common after transplantation?
o Infection, Cytomegalovirus, and Graft versus Host Disease
o Hepatitis A, Hepatitis C
o Colon cancer and rectal bleeding
o Hyperlipidemia and Hypertension
5. Which of these preventative measures are important?
o Drinking alcohol heavily with more than 2 drinks a day
o Staying physically active (2.5 hours each week with moderate exercise)
o Eating an unhealthy diet with plenty of fast food.
o Sitting on the couch for 8-10 hours a day
6. Which best describes a scenario that should be reported to your oncologist?
o You should never report any symptoms

127
o Exposure to chickenpox or shingles
o A headache that resolved within 2 hours
o An increased appetite
7. Which best describes common medications that you will be prescribed after
your transplantation?
o Antivirals
o Immunosuppressants
o Antifungals
o All of the above
8. If your central catheter site becomes painful, swollen, or red you should?
o Just remain calm the pain will go away
o Try to take the dressing off to relieve the pain
o Call the clinic or your oncologist immediately
o Take Tylenol this is a normal reaction
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Appendix K: EORTC-QLQ-INFO25 QUESTIONNAIRE
We are interested in the information you have received about aspects of your disease and its
treatment, in order to improve your health care. Please answer ALL questions yourself by
circling the number that best applies to you. There are no right or wrong answers. The
information that you provide will remain strictly confidential.
During your stem cell transplant hospitalization, how much information did you
received on:
Not at all
A little Quite a bit Very much
1. The purpose of any medical tests you 1
had undergone?

2

3

4

2. The results of the medical tests you
received?

1

2

3

4

3. The medical treatment (chemotherapy, 1
radiotherapy, or surgery)?

2

3

4

4. The possible side-effects
of your treatment?

1

2

3

4

5. Tips of managing your illness at home? 1

2

3

4

6. Did you receive written information at discharge?

Yes

No

7. Do you wish to receive more information?
Yes
No
a. If yes, please specify on which topics?
______________________________________________________________________________
______________________________________________________________________________
8. Do you wish that you had received less information?
a. If yes, please specify on which topics?

9. Overall has the information you
received been helpful?

Not at all
1

A little
2

Yes

Quite a bit
3

Adapted from https://www.eortc.be/qol/INFO25/INFO25%20English.pdf

No

Very much
4
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Appendix L: Pre-Transplant Script
Hello _________________,

My name is Chantaney Williams and I am a doctoral nurse practitioner student at the University
of Arkansas. I am working here at UAMS in Little Rock, AR to begin a survivorship care plan
program following allogenic stem cell transplantations. Previously, patients have been
discharged from the hospital with no additional information given about post-transplantation
care, but current research indicates survivorship care plans are helpful with follow-up care and
additional information on ways to reduce coming back to the hospital. The purpose of this
project is to decrease 30-day readmissions to the hospital among allogenic stem cell transplant
patients, allowing you to have information at your fingertips about common complications,
preventative measures, and decreasing the cost of readmissions from your transplant procedure.

Because you are scheduled for a stem cell transplant, your participation would include a short
knowledge test prior to discharge and receiving a survivorship care plan prior to going home. In
the outpatient oncology clinic, you will receive two questionnaires at your initial visit and then
one questionnaire once weekly for three weeks. Your participation would be greatly appreciated
in efforts to improve our stem cell program. Your willingness to participate in this project will
help with future efforts of improving our program for the future.

Would you be willing to participate in this project?

Thank you for your time,

Chantaney Williams, University of Arkansas Mann DNP Student
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Appendix M Discharge Script
Hello _________________,

Please take 10-15 minutes to complete this short SCP Questionnaire that will be used as a tool to
help with future research to improve the Survivorship Care Plan. This questionnaire is seeking to
assess your level of knowledge on preventative measures and complications post-transplantation.
If you have any questions or need clarification, please do not hesitate to ask.

This survivorship care plan consists of information that is pertinent to your allogenic stem cell
transplant. This packet can be shared between you and your oncologist to help make decisions
about your care. Transplant follow-up care is important to protecting your health. This packet
contains your personalized care plan, steps you can take to get the most out of your care plan,
and how to get your questions answered. Additional information is provided on preventative
measures, common complications, and common medications. Your survivorship care plan is
organized in sections to better assist you with finding the information needed once discharged.

Please take time review this information again at home and familiarize yourself with tips you can
use to prevent infections and decrease your chances of being readmitted to the hospital. If you
have any questions, please feel free contact the oncology clinic or ask your oncologist. Thank
you for participating in the Survivorship Care Plan program. We hope the efforts of this project
will serve as a reference point upon your discharge.

Thank you for your time,

Chantaney Williams, University of Arkansas Mann DNP Student
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Appendix N: Consent Form
The Effects of a Survivorship Care Plan on Hospital Readmission Rates in Allogenic Stem
Cell Transplant Patients

PRINCIPAL INVESTIGATOR
Chantaney Williams
University of Arkansas Eleanor Mann School of Nursing
606 N. Razorback Rd.
1-479-575-3904
crw048@uark.edu
FACULTY ADVISOR
Dr. Michele Kilmer
University of Arkansas Eleanor Mann School of Nursing
606 N. Razorback Rd.
1-479-575-3581
michelekl@uark.edu
PURPOSE OF PROJECT
You are being asked to take part in a Doctoral Nursing Practice (DNP) project. Before you
decide to participate in this project, it is important that you understand why the project is being
done and what it will involve. Please read the following information carefully. Please ask the
principal investigator if there is anything that is not clear or if you need more information.
The purpose of this project is to reduce 30-readmission rates among allogenic stem cell
transplant (SCT) post transplantation by evaluating post-transplantation education via a
survivorship care plan (SCP) with a survey at two days, one week, two weeks, and three weeks
after discharge.
The aim for this project is to utilize survivorship care plans for allogenic stem cell transplant
patients prior to hospital discharge in order to reduce 30-day readmission rates. Following
protocol implementation, this project expects to track readmission rates in efforts to reduce
readmission rates among allogenic patients by 10% by March 2021.
PROJECT PROCEDURES
The following is the suggested procedures that will take place:
• Patient will be complete a survivorship care plan questionnaire prior to discharge
• Patient will be provided with survivorship materials upon discharge on the common
complications and preventative measures
• Patient will participate in weekly follow-up survivorship questionnaires for three weeks
in the outpatient clinic
• Patient will receive a follow-up phone call if outpatient clinic appointment is missed
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•

Data recorded for your medical record will include demographic data, number of
readmissions, readmission diagnosis, complications within 30 days of discharge,
interventions implemented to prevent readmission, complications treated, length of stay
with readmission, the number of attended visits in the outpatient clinic, and the number of
missed appointments in the outpatient clinic

RISKS
There should be very minimal risks for this project however, emotional and psychological strains
can occur. There is a low risk of stress and anxiety for yourself and caregiver assuming care
responsibility at home.
BENEFITS
Benefits to participating in this project include:
• Decreasing 30-day readmission rates
• Prevention of complications post-transplant
• Increase patient understanding of common complications and preventative measures
• Decreased cost for patients and hospital associated with 30-day readmissions

CONFIDENTIALITY
Participation in this study includes gathering information that could identify you and your
personal health information. This information will be kept only for the length of the study (six
months). After that time, it will be destroyed or de-identified, meaning we will replace your
identifying information with a code that does not directly identify you. The principal
investigator will keep a link that identifies you to your coded information, but this link will be
kept secure and available only to the principal investigator. Any information that can identify
you will remain confidential.
To assure patient confidentiality, the principal investigator will keep data in a computer that is
password protected. Notes, interview transcriptions, and any other identifying participant
information will be secured in a locked file cabinet in the personal possession of the principal
investigator.
Participant data will be kept confidential to the extent allowed by law and University policy.
The researcher is legally obligated to report specific incidents which include, but may not be
limited to, incidents of abuse and suicide risk.

CONTACT INFORMATION
If you have questions at any time about this project, or you experience adverse effects as the
result of participating in this project, you may contact the principal investigator, whose contact
information is provided on the first page. If you have questions regarding your rights as a study
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participant, or if problems arise which you do not feel you can discuss with the Principal
Investigator, please contact the University of Arkansas Institutional Review Board at 1-479-5752208.
VOLUNTARY PARTICIPATION
Your participation in this project is voluntary. It is your decision whether or not to take part in
this project. If you decide to take part in this project, you will be asked to sign a consent form.
After you sign the consent form, you are still free to withdraw at any time and without giving a
reason. Withdrawing from this project will not affect the relationship you have, if any, with the
principal investigator. If you withdraw from the project before data collection is completed, your
data will be returned to you or destroyed.

CONSENT
I have read and I understand the provided information and have had the opportunity to ask
questions. I understand that my participation is voluntary and that I am free to withdraw at any
time, without giving a reason and without cost. I understand that I will be given a copy of this
consent form. I voluntarily agree to take part in this project.

Participant's signature ______________________________ Date __________

Investigator's signature _____________________________ Date __________
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Appendix O: Copy of Approval Letters
From: no-reply@eortc.be <no-reply@eortc.be>
Sent: Monday, July 6, 2020 1:22 AM
To: Chantaney Williams <crw048@uark.edu>
Subject: Your request for an EORTC-questionnaire Request ID : 68956

Dear chantaney williams,
Thank you for registering on the EORTC Quality of Life Group website.
Your registration to obtain permission to use our tools has been approved. During the
registration process you agreed to our terms and conditions regarding the academic use of
our questionnaires. You can review the terms and conditions here.
Please find below the links to the requested tools:
Information Module (INFO25) - English

Scoring Manuals:

Appendix P: Copy of Site’s IRB Approval
Institutional Review Board
4301 West Markham, #636
Little Rock, AR 72205-7199
501-686-5667
501-686-7265 (fax)
http://irb.uams.edu/
FWA00001119
10/16/2020
PI Name: Williams, Chantaney
PI Department: ICE NRSL Medical Onc & Transplant
Number: 261885
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Project Title: The Effects of a Survivorship Care Plan on Hospital Readmission Rates in
Allogenic Stem Cell Transplant Patients
NOT HUMAN SUBJECT RESEARCH DETERMINATION
The Institutional Review Board Director or Designee reviewed your material and determined
that this project is NOT human subject research as defined in 45 CFR 46.102, and therefore
it does not fall under the jurisdiction of the IRB review process.
Committee Notes/Comments:

•

Per the information provided, this is implementation of a care initiative primarily
intended to improve local patient outcomes (as opposed to primarily intended to
create generalizable knowledge). As such, this does not meet the definition of human
subjects research and IRB oversight is not required.

Please keep the IRB advised of any changes that may require the project to be re-classified
as human subject research.
If you have any questions, please contact an IRB administrator at 501-686-5667.
Click here to access study.
Error! Filename not specified.
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Appendix Q: Copy of Approval Letters
Streamlyne Research <production-research@uasys.streamlyne.org>
Mon 1/11/2021 9:43 AM

Your Action List has an eDoc(electronic document) that needs your attention:
Document ID: 181610
Initiator:
System, Notification
Type:
Add/Modify KcNotificationDocument
Title:
Protocol 2010293729 is Approved as Exempt

To respond to this eDoc:
Go
to https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fresearch.uasys.streaml
yne.org%2Fken%2FDetailView.form%3FdocId%3D181610%26command%3DdisplayActionListVie
w&amp;data=04%7C01%7Ccrw048%40uark.edu%7C8c79d6560000406a750208d8b647ac1b%7C
79c742c4e61c4fa5be89a3cb566a80d1%7C0%7C0%7C637459766228648838%7CUnknown%7CT
WFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7
C1000&amp;sdata=DIVOmcxnnmrqA9S8t8l55IkVo%2FHBZCjcXBrtYn4EraY%3D&amp;reserved=
0
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Appendix R: HIPAA Completion Forms
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Appendix S. Proposed Gantt Chart

Appendix S: Final Gantt Chart
6-Oct-20
DNP Proposal Presentation
IRB Approval
Conduct Chart Review
Conduct Educational Training w/staff
Implement SCPs
Collect Data
Analyze Data

Prepare to present to committee
Prepare for presentation to site
Prepare for dissemination

25-Nov-20

14-Jan-21

5-Mar-21

24-Apr-21
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Appendix T: Implementation Timeline
Implementation
Timeline
1/11/2021

Progress
Received IRB Approval

1/12/2021

Implementation process
began
Nursing
education/consent/training
Open to accepting new

1/13/2021

First SCT participant to
enroll in project

1/14/2021

Two SCT participants were
enrolled in project

1/18/2021

One SCT participant
enrolled in project

1/21/2021

*Weekly team meetings*
One SCT participant
enrolled in project

1/29/2021

*Weekly team meetings*

2/3/2021

Two SCT participant
enrolled in project

2/4/2021

Weekly team meetings*

2/5/2021

New Changes

*Weekly clinic team
meeting*

*PDSA Cycle: Inpatient
Staff and Consenting.
Clarification of when to
receive signed consents

*PDSA Cycle: Decreased
Nurse Participation.
Incentive measures put in
place to increase staff
participation
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2/7/2021
2/14/2021

*Weekly team meeting*
*Weekly clinic team
meeting*

2/17/2021

One SCT participant
enrolled in project

2/19/2021

*Weekly team meetings*

2/22/2021

One SCT participant
enrolled in project

2/24/2021

One SCT participant
enrolled in project

3/1/2021

*Weekly team meetings*

3/2/2021

One SCT participant
enrolled in
project

3/4/2021

*Weekly team meetings*

3/7/2021

Last day to enroll
participants

3/8/2021

*Weekly team meetings*

*PDSA Cycle* New
Discharge Process
implemented the SCP
questionnaire the night
prior to discharge
Data collection began as
patients begin to discharge
after 30-days posttransplantation
*PDSA Cycle* Outpatient
follow-up appointments
occurred with
implementation of SCP
Questionnaire & EORTCQLQ 25 Questionnaire
during initial
appointments.

Enrollment and consent
period ends for
implementation
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3/15/2021

*Weekly team meetings*

3/23/2021

*Weekly team meetings*

3/27/2021

End of implementation
period
DNP Intensive
presentation to CON
Presentation at Academic
Facility
Dissemination of Results

4/13/2021
4/28/2021
5/2/2021

All final data collected
from outpatient setting to
be entered into Qualtrics
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Appendix U: Proposed Flow Chart
Patient arrives to
hospital admission
area

anoti

Patient experiences nadir
phase and becomes
neutropenic

Allogenic Stem Cell
Transplantation occurs

Admission department notifies
bed control for room
assignment

Await for patient to begin
engraftment 7-21 post
transplant
Patient receives
pre-conditioning
chemotherapy for
transplant

Room paged out to
charge nurse and
the patient is
assigned

Patient admitted to bone
marrow unit

Engraftment occurs discharge
planning over the next 2-3
days

Patient invited to
participate in project
w/goals & aims explained
prior to signing consent
SCP Questionnaire
and education material
given the night before
planned discharge

On-call
Resident
notified of
patient’s
arrival

Patient’s admission
process complete
Discharge occurs the next
day to a local housing within
20 minutes of the hospital

Key Code:
Symbol

Name

Function

143

Oval

Represents a start and
end point

Arrows

Represent a connection
between two related points

Parallelogram

Represents input/out

Square

Represents a process

Circle

Represents a decision
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Patient arrives to
hospital admission
area

anoti

Admission department notifies
bed control for room
assignment

Room paged out to
charge nurse and
the patient is
assigned

Appendix V: Final
Allogenic Stem Cell Flow Chart

Final Process Flow Chart

Engraftment occurs discharge
planning over the next 2-3
days

Await for patient to begin
engraftment 7-21 post
transplant

Patient admitted to bone
marrow unit

Patient experiences nadir
phase and becomes
neutropenic

SCP Questionnaire
and education
material given the
night before
planned discharge

Discharge occurs the next
day to a local housing within
20 minutes of the hospital

Patient attends initial
outpatient follow up
appointment 1 -2 days
post discharge

On-call
Resident
notified of
patient’s
arrival

Allogenic Stem Cell
Transplantation occurs
Patient’s admission
process complete

Patient invited to
participate
in to
project
Key Guide
Process Chart
w/goals & aims explained
prior to signing consent

Patient receives
pre-conditioning
chemotherapy for
transplant

SCP Questionnaire
and EORTC-QLQ
25 are initiated at
initial appointment
by ARPN

Data collected by principal
investigator

145

Symbol

Name

Function

Oval

Represents a start and
end point

Arrows

Represent a connection
between two related points

Parallelogram

Represents input/out

Square

Represents a process

Circle

Represents a decision

146
Appendix W: Final Chair Approval

College of Education and Health Professions
Eleanor Mann School of Nursing

Appendix M: DNP Project Final Paper Evaluation Rubric
Project Title: The Effects of a Survivorship Care Plan on Hospital Readmission Rates in Allogenic Stem
Cell Transplant Patients
Student Name: Chantaney Williams

Faculty Chair: Michele Kilmer, DNP, APRN, CPNP-PC

Date: April 10, 2021
Satisfactory as
presented
Abstract
Summarizes content of project
Includes an overview of the
project's background and review of
literature, purpose, method, results,
and conclusion
Contains approximately 250 words
Uses keywords
Background and Significance
Background information
demonstrates the focused need or
problem
Includes global, national, state, and
local data if applicable
Problem and change idea are
clearly identified
Need, feasibility and significance
are clearly presented
Problem Statement
Problem clearly described in one
sentence
Problem is specific to clinical site
Problem is supported by literature
Purpose Statement
Purpose clearly described in one
sentence
Details are provided to support the
purpose statement
Scope of project realistic and
appropriate
PICOT Question
PICOT Question relates to project
PICOT Question follows template
PICOT Question clearly stated
Needs Assessment
Description for how need for
project was determined

X
X

X
X

X
X
X

X
X
X
X
X
X

X
X
X
X

Unsatisfactory with the following
recommendations
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Includes agency data supporting
project
Compares global, national, state,
and local data with site data
Includes Global Aim agreement
Includes Process Flowchart
Objectives and Aim
Explains overarching aim of
project
Describes objectives to support the
project aim
Review of Literature
Literature review supports
significance/relevance of problem/
project/intervention
Literature review presents an indepth current state of knowledge
Concepts are integrated and
synthesized
Trends, patterns, gaps, or
relationships in concepts are
identified
Evidence Table provides context
for project purpose and
intervention
Statistical information is presented
Explanation of how project will
address identified concerns
Theoretical Framework
Framework concepts are explained
and detailed in relation to the
project process
Concept map is included
Project Description
Project objectives stated in feasible
and measurable terms
Congruence of organizations’
strategic plan to project is
described
Project Design
Project design is clearly stated
Design is appropriate for
objectives
Clear rationale for actions/method
Setting is clearly described
Study population is clearly
described
Study intervention, implementation
and methods/tools are feasible and
clearly described
Study instruments are described
and included
Data parameters are explained
Resources/supports are detailed

X
X
X
X
X
X

X

X
X
X

X

X
X

X

X
X
X

X
X
X
X
X
X

X
X
X
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Risks/threats and benefits are
noted
Methods for subject recruitment is
explained
Materials for subject recruitment is
provided
Consent procedures are explained,
and informed consent form is
provided
Subject costs and compensation is
detailed
Timeline is clearly described and
feasible
Budget is provided
Implementation Phase
Describes the implementation
process as it unfolded
Notes any changes from proposal
timeline and gives rationale for
changes
Outlines process cycles, detailing
changes encountered and how they
were addressed
Details contextual elements that
interacted with the intervention
Identifies deviations in
implementation period and gives
rationale for changes
Discusses results of any actions
taken to address challenges
Discusses interprofessional team
dynamics
Compares new process flow chart
to original flow chart, noting if
improvements resulted from
intervention
Includes table depicting steps of
intervention and their evolution
over time with modifications made
during the project
Evaluation of Results
Assesses process measures and
how they affected project results
Uses data and/or statistical analysis
to evaluate outcome measures
Discusses missing data, if
applicable
Method of analysis clearly
described
for each outcome measurement
Identifies variation within the data,
if applicable
Project results are clearly
connected with intervention

X
X
X
X

X
X
X
X
X

X

X
X

X
X
X

X

X
X
X
X

X
X
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Describes any unintended
consequences such as unexpected
benefits, problems, failures, or
costs associated with project
intervention
Evaluation is coherent and
consistent with project plan
Evaluation measures linked to
project objectives
Discussion
Discusses impact of the project on
people and systems
Discusses results in context of
other studies or quality
improvement projects in the
literature
Discusses possible reasons for any
differences between observed and
anticipated outcomes
Discusses economic and cost
benefits of project
Explains strategic trade-offs if
applicable
Limitations
Identifies factors that may have
affected the project results
Identifies and discusses factors that
might limit transferability to other
organizations or systems
Identifies factors that may have
affected the internal validity such
as confounding, bias, or
imprecision in the design,
methods, measurement, or analysis
Identifies efforts made to minimize
and adjust for limitations
Sustainability
Details usefulness of project
Addresses how the intervention
will continue now that project is
completed
Recommendations
Suggests next steps of potential
follow-up projects
Explains project impact on
healthcare quality and safety
Identifies health policy
implications
Dissemination
Plan for disseminating project
results to agency is detailed
Plan for disseminating project
results professionally is detailed
Conclusion

X

X
X

X
X

X

X
X

X
X

X

X

X
X

X
X
X

X
X

.
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Makes a statement about the
overall results of the project
Lists key findings, including
relevance to project’s aim
Identifies strengths of the project
Project’s contribution to nursing
practice knowledge is addressed
Implications for nursing practice,
patient care, or health care delivery
and future interventions related to
problem and purpose
References
Current and accurate reference list
present
Approvals
Letters of support/Statement of
Mutual Agreement from
cooperating agencies provided
Informed consent, if necessary,
meets human subject requirements
Approvals are provided as
appendices
Writing and organization
APA format followed
appropriating; writing is scholarly
and clear; appropriate for doctoral
level education
Paper is submitted to plagiarism
software prior to presentation;
copy of plagiarism report is
included

X
X
X
X
X

X

X

X
X

X

X

Committee comments:
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
Overall Evaluation of the DNP Project Final Paper
__X___ Accept final paper
_______Require the following revisions:
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
Signature of Chair on behalf of the Committee:
Michele Kilmer, DNP, APRN, CPNP-PC

Date: April 19, 2021
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